Immune system disorder
MONDO:0005046A disorder resulting from an abnormality in the immune system.
Also known as: disease of immune system, disease or disorder of immune system, disorder of immune system, immune disease, immune disorder, immune dysfunction, immune system disease or disorder, immune system disorder
12340 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 4851 trials in this tab.
-
Engineered immune cells take aim at Hard-to-Treat leukemia
⭐️ CURE ⭐️ Recruiting nowThis early-stage trial is testing an investigational therapy called B019, which uses a patient's own immune cells engineered to recognize and attack leukemia cells. The study focuses on people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard…
Phase: PHASE1 • Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. • Aim: ⭐️ CURE ⭐️
Last updated Aug 18, 2026 00:00 UTC
-
Can a One-Time CAR-T therapy outsmart myeloma and replace lifelong treatment?
⭐️ CURE ⭐️ Recruiting nowThis Phase III trial is testing whether a single infusion of AZD0120, a CAR-T therapy that targets two proteins on myeloma cells, can keep the cancer at bay better than continuous standard treatment. It enrolls adults newly diagnosed with multiple myeloma who are not eligible for…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
Can a One-Two punch of CAR-T and lenalidomide beat tough leukemia?
⭐️ CURE ⭐️ Recruiting nowThis trial is testing whether combining anti-CD19 CAR-T cell therapy with the drug lenalidomide can safely and effectively treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatments. Participants…
Phase: PHASE1, PHASE2 • Sponsor: Vitebsk Regional Clinical Cancer Centre • Aim: ⭐️ CURE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
⭐️ CURE ⭐️ Recruiting nowThis trial is testing an experimental therapy called CD22 CAR T cells in adults with certain types of B cell lymphomas that have come back or not responded to previous treatments. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack…
Phase: PHASE1 • Sponsor: Stanford University • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
Can donor immune cells be engineered to fight blood cancer?
⭐️ CURE ⭐️ Recruiting nowThis trial tests a new type of cell therapy called KCAT19 for people aged 16 to 65 with advanced B-cell blood cancers that have relapsed or not responded to at least two prior treatments. The therapy uses immune cells from a donor's cord blood, which are modified to recognize and…
Phase: PHASE1 • Sponsor: University College, London • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Pfizer launches massive trial of c. diff vaccine for seniors
⭐️ VACCINE ⭐️ Recruiting nowThis study tests whether a vaccine can prevent C. difficile infection in adults 65 and older. About 32,000 participants will receive either the vaccine or a placebo shot. The study will track infections and side effects over up to three and a half years.
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo aims to outperform standard therapy for Hard-to-Treat blood cancers
Disease control Recruiting nowThis phase 3 trial is testing whether a new drug, nemtabrutinib, combined with venetoclax works better than the current standard of venetoclax plus rituximab for people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 735 p…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Could a blood trait change how we dose chemo?
Disease control Recruiting nowThis study tests whether adjusting cancer drug doses for people with the Duffy null blood trait can reduce treatment delays and dangerous fevers. About 90 participants with multiple myeloma or triple-negative breast cancer will receive standard chemotherapy with modified dosing g…
Phase: PHASE1 • Sponsor: Andrew Hantel, MD • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New pill shows promise against tough blood cancers
Disease control Recruiting nowThis phase 2 study tests an oral drug called nemtabrutinib in about 490 people with blood cancers like chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenstrom's macroglobulinemia. The goal is to see if the drug can shrink tumors and control the cancer, while also chec…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New pill hopes to slow rare brain disease in kids
Disease control Recruiting nowThis study tests an oral drug called nizubaglustat in children and teens aged 4 and older with Niemann-Pick type C disease, a rare genetic disorder that affects movement and thinking. Participants will take the drug or a placebo for 18 months to see if it slows the disease and im…
Phase: PHASE3 • Sponsor: Azafaros B.V. • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Combination therapy aims to outsmart tough lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether adding the drug nemtabrutinib to a CAR T-cell therapy called brexu-cel can help people with mantle cell lymphoma that has come back or not responded to treatment. Nemtabrutinib blocks a protein that helps cancer cells grow, while brexu-cel uses a …
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Poop pills may help lymphoma patients tolerate powerful cancer treatment
Disease control Recruiting nowThis study tests whether fecal microbiota transplantation (FMT) can reduce gut-related side effects from antibiotics in 40 adults with B-cell lymphoma who are receiving standard CAR-T cell therapy. Participants will receive FMT alongside their cancer treatment to see if it improv…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New triple therapy aims to boost survival in frail AML patients
Disease control Recruiting nowThis phase 3 trial will test whether adding the drug quizartinib to the standard two-drug combination (venetoclax and azacitidine) helps adults with newly diagnosed acute myeloid leukemia (AML) live longer. The study includes 376 people aged 18 and older who cannot receive intens…
Phase: PHASE3 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can patients stop Anti-Rejection drugs sooner after transplant?
Disease control Recruiting nowThis study tests whether patients can safely stop the drug tacrolimus earlier than usual after a stem cell transplant. Tacrolimus is given to prevent graft-versus-host disease (GVHD), but newer methods have lowered GVHD risk. The trial will enroll 50 people with blood cancers and…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can better talks boost lupus med adherence? new study aims to find out.
Disease control Recruiting nowThis study tests a program called CO-LEAD that trains doctors to use effective communication strategies and a patient survey to identify barriers to taking lupus medications. Researchers will enroll 480 patients and their clinicians at two academic centers. The goal is to see if …
Phase: NA • Sponsor: Duke University • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can a Two-Pill combo calm the Gut's inflammatory fire?
Disease control Recruiting nowThis early-stage trial explores whether adding two experimental capsules, ND-12 and H-6, to standard mesalazine treatment can better control chronic inflammatory diarrhea in adults, including those with active ulcerative colitis. Participants will take the combination or a placeb…
Phase: EARLY_PHASE1 • Sponsor: The Second Hospital of Nanjing Medical University • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Cancer drug nivolumab takes on EBV-Linked tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolu…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New hope in blood cancer battle: Next-Gen drug tested against standard therapy
Disease control Recruiting nowThis study tests whether a newer drug called pirtobrutinib works better than the current standard drug ibrutinib for people with chronic lymphocytic leukemia or small lymphocytic lymphoma. About 737 adults who need treatment for their cancer will be randomly assigned to receive o…
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New combo therapy aims to boost remission in IDH2-Mutated AML
Disease control Recruiting nowThis phase II trial tests whether adding enasidenib to standard ASTX727 and venetoclax improves remission rates in older adults (or younger unfit patients) with newly diagnosed IDH2-mutated acute myeloid leukemia (AML). About 93 participants will be randomly assigned to receive e…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can an ancient herbal remedy tame rheumatoid arthritis?
Disease control Recruiting nowThis study tests whether adding a Chinese herbal formula (Si Miao Xiao Bi Tang) to standard rheumatoid arthritis medication can improve symptoms. About 132 adults with active RA will receive either the herbal medicine or a placebo for 12 weeks. The main goal is to see if more peo…
Phase: PHASE2, PHASE3 • Sponsor: Singapore General Hospital • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control Recruiting nowThis early-phase trial is testing a new cell therapy called CD83 CAR T cells in 26 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy uses a patient's own immune cells, genetically modified to recognize and attack a protein (CD83…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Could existing cancer drugs tackle rare tumors? new trial aims to find out
Disease control Recruiting nowThis trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can a simple patch stop diabetes device skin woes?
Disease control Recruiting nowThis trial tests whether a silicone-based or a hydrocolloid patch placed under insulin pumps or glucose monitors can prevent contact dermatitis from coming back in children aged 2-18. Participants will use different patches and attend visits for skin exams, ultrasounds, and quest…
Phase: NA • Sponsor: Steno Diabetes Center Copenhagen • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Engineered immune cells take on metastatic tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New combo therapy aims to improve AML treatment for patients with specific gene changes
Disease control Recruiting nowThis early-phase trial tests whether adding a menin inhibitor (SNDX-5613) to standard chemotherapy can better control acute myeloid leukemia (AML) in people with certain gene changes (NPM1 or MLL). About 38 newly diagnosed adults will receive the combination to find the safest do…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New hope for kidney disease: Zigakibart's Long-Term safety under study
Disease control Recruiting nowThis study looks at the long-term safety of a drug called zigakibart for adults with IgA nephropathy, a kidney disease. It is for people who have already finished a previous zigakibart study. Researchers will monitor side effects and check kidney function over 96 weeks.
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New hope for young AML patients: targeted drug combo tested in phase 2 trial
Disease control Recruiting nowThis study tests two different drug combinations for younger adults with a specific type of acute myeloid leukemia (CBF-AML). One group gets standard chemotherapy plus a targeted antibody, while the other gets the same chemotherapy plus a newer targeted pill. The goal is to see w…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Electric jolt workouts: a new hope for paralyzed limbs?
Disease control Recruiting nowThis study tests whether exercise using electrical stimulation can improve muscle strength and endurance in people with lower limb paralysis from conditions like spinal cord injury, stroke, or multiple sclerosis. Participants will use devices that send electrical signals to their…
Phase: NA • Sponsor: Louis Stokes VA Medical Center • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New hope for myeloma patients: could a smart drug outperform standard therapy?
Disease control Recruiting nowThis phase 3 trial will compare two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or refuse a stem cell transplant. About 500 participants will receive either belantamab mafodotin or daratumumab, both combined with standard drugs (bor…
Phase: PHASE3 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New liquid drug offers hope for kids with severe eczema
Disease control Recruiting nowThis 24-month study tests the long-term safety and effectiveness of abrocitinib, a liquid oral medication, in children aged 2 and older with moderate-to-severe atopic dermatitis (eczema). About 500 participants will receive the drug, with or without topical creams. The goal is to…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New drug combo aims to keep childhood leukemia at bay after transplant
Disease control Recruiting nowThis phase 1 trial tests the safety and best dose of an oral drug called ASTX727 (a combination of cedazuridine and decitabine) along with filgrastim in children with high-risk acute myeloid leukemia (AML) that has returned or not responded to treatment. All participants have alr…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Could CAR t cells tame scleroderma? new trial launches
Disease control Recruiting nowThis early-stage study tests a new treatment called CABA-201 for people with systemic sclerosis (scleroderma), a disease that causes hardening of the skin and can damage organs. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that dr…
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New hope for HIV patients with blood cancer: safer bone marrow transplants on the horizon?
Disease control Recruiting nowThis study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and maraviroc) can safely prevent graft-versus-host disease after a half-matched bone marrow transplant in people living with HIV who also have a blood cancer. The trial involves 265 participants…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Engineered immune cells take on lupus kidney disease
Disease control Recruiting nowThis phase 2 trial is testing a new treatment called FT819 for people with lupus nephritis, a serious kidney complication of lupus. FT819 is made from donor immune cells that are engineered to target and destroy faulty B cells. The study will enroll 53 participants and aims to se…
Phase: PHASE2 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Double-Barreled CAR t takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a new treatment called AZD0120 for people with multiple myeloma that has come back or stopped responding to at least three prior therapies. AZD0120 is a personalized cell therapy that reprograms a patient's own immune cells to attack two targets on myeloma cells …
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New hope for rare blood cancers: pacritinib trial opens for teens and adults
Disease control Recruiting nowThis study tests an oral drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood cancers (MDS/MPN). The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New combo tackles tough myeloma: early trial hopes for better control
Disease control Recruiting nowThis early-phase trial is testing a combination of two drugs—teclistamab and iberdomide—in people with multiple myeloma that has come back or stopped responding to treatment. The goal is to find the safest and most effective dose of iberdomide when used with teclistamab. About 26…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New combo therapy targets hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called UB-VV111 given with rapamycin for people with certain types of blood cancer (large B-cell lymphoma or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The main goal is to check the saf…
Phase: PHASE1 • Sponsor: Umoja Biopharma • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New asthma pill shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests an oral drug called KT-621 in 264 adults with moderate to severe eosinophilic asthma that is not well controlled by current treatments. Participants will take either KT-621 or a placebo daily for several weeks. Researchers will measure changes in lung function an…
Phase: PHASE2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New hope for kids with rare immune cell cancer: drug trial launches
Disease control Recruiting nowThis study tests a drug called tovorafenib (DAY101) in children and young adults (ages 6 months to 22 years) with Langerhans cell histiocytosis that has returned or not responded to treatment. The drug works by blocking enzymes that help cancer cells grow. Researchers will check …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Brain zaps before therapy may help kick cocaine habit
Disease control Recruiting nowThis study tests whether a non-invasive brain stimulation technique called rTMS, given before cognitive-behavioral therapy, can help adults with cocaine use disorder quit. Thirty participants will receive either real or sham rTMS daily for 3 weeks, followed by 12 weeks of weekly …
Phase: NA • Sponsor: New York State Psychiatric Institute • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New pill could ease lupus skin rashes in major trial
Disease control Recruiting nowThis study tests a drug called enpatoran for people with lupus who have active skin rashes or lesions. About 202 participants will take either enpatoran or a placebo twice daily for 24 weeks, alongside their usual treatments. The goal is to see if the drug can significantly impro…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can a stem cell transplant fix a rare genetic immune disorder?
Disease control Recruiting nowThis study tests whether a stem cell transplant from a healthy donor can treat GATA2 deficiency, a rare genetic condition that weakens the immune system and raises the risk of leukemia. Participants aged 6 to 70 with GATA2 mutations will receive chemotherapy or radiation before t…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New eczema drug shows promise for kids in Late-Stage trial
Disease control Recruiting nowThis study tests whether abrocitinib, a liquid medicine, can improve moderate-to-severe eczema in children aged 6 to 12. About 150 kids will be randomly assigned to receive either the drug or a placebo for 16 weeks. The goal is to see if the medicine clears the skin and reduces i…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Pfizer launches early trial of PF-07994525 for Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage study tests a new drug, PF-07994525, in about 120 adults with advanced multiple myeloma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. The study has two parts:…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New combo therapy aims to slow progressive MS disability
Disease control Recruiting nowThis study tests whether adding a new drug (RO7268489) to the standard MS treatment ocrelizumab can slow disability progression in adults with progressive multiple sclerosis. About 360 participants will receive either the new drug or a placebo, and researchers will track walking …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New drug combo aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage study is testing whether combining two drugs—teclistamab and mezigdomide—is safe and effective for people with multiple myeloma that has come back or stopped responding to other treatments. About 18 participants will receive the drugs in a specific sequence. The …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New drug aims to stop immune attack after stem cell transplants
Disease control Recruiting nowThis study tests a drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant. Fifty adults with blood cancers like leukemia will receive six weekly doses of BPC200…
Phase: PHASE2 • Sponsor: BioPhoenix Co., Ltd. • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
New hope for stubborn eczema? abrocitinib tested after biologics fail
Disease control Recruiting nowThis study is tracking 150 adults and teens with moderate-to-severe eczema who have already tried up to two biologic drugs without success. Researchers want to see how well the oral medication abrocitinib (Cibinqo) works in real-world settings. The main goals are to measure impro…
Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Scientists train immune cells to hunt down mutated blood cancers
Disease control Recruiting nowThis early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Personalized chemo boosts CAR T-Cell success in young leukemia patients
Disease control Recruiting nowThis study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Could a common arthritis drug tame rare immune disease symptoms?
Disease control Recruiting nowThis early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also check…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 18, 2026 00:00 UTC
-
Can gentler therapy beat harsh chemo for tough leukemia?
Disease control Recruiting nowThis phase 3 trial tests whether less intense drug combinations can control relapsed or refractory acute myeloid leukemia (AML) as well as high-dose chemotherapy. About 339 adults whose AML has returned or not responded to initial treatment will be randomly assigned to either a l…
Phase: PHASE3 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for celiac sufferers: drug targets gut damage despite strict diet
Disease control Recruiting nowThis study tests an experimental drug called DONQ52 in people with active celiac disease who still have gut damage and symptoms even after following a gluten-free diet for at least a year. About 92 adults will receive either the drug or a placebo to see if it can heal the small i…
Phase: PHASE2 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New Antibody-Drug combo aims to tackle tough lymphoma
Disease control Recruiting nowThis study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to treatment. About 290 adults will be randomly assigned to receive either the new combination o…
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New shot shows promise for Long-Term control of bleeding disorder
Disease control Recruiting nowThis study tests the long-term safety of a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing easy bruising and bleeding. About 150 participants who completed earlier mezagitamab studies w…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for leukemia patients: asciminib trial launches
Disease control Recruiting nowThis Phase 2 trial tests the drug asciminib in 50 adults newly diagnosed with chronic myeloid leukemia (CML). The goal is to see if asciminib can control the disease and to check for side effects. Participants take the drug by mouth, and researchers monitor their health closely.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for AML patients in india: drug combo aims for remission without intensive chemo
Disease control Recruiting nowThis study tests a combination of two drugs, venetoclax and azacitidine, in about 100 adults in India with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see if the combo can put the cancer into remissio…
Phase: PHASE4 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for kids with tough leukemia: experimental drug enters human testing
Disease control Recruiting nowThis early-stage study is testing an experimental drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check the drug's safety and how it moves through the body. Partici…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for AML patients: Triple-Drug combo targets Tough-to-Treat leukemia
Disease control Recruiting nowThis study tests whether adding pivekimab sunirine to the standard drugs venetoclax and azacitidine helps adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 660 participants will be randomly assigned to receive ei…
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can trained immune cells stop blood cancer relapse?
Disease control Recruiting nowThis trial tests whether giving patients special immune cells, called TAA-T, after a stem cell transplant can help prevent high-risk blood cancers like acute myeloid leukemia from coming back. The cells are designed to recognize three common tumor markers and attack any remaining…
Phase: PHASE1 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug aims to save sight in optic neuritis patients
Disease control Recruiting nowThis Phase 3 trial tests whether privosegtor, a neuroprotective drug, can improve vision recovery in people having their first episode of optic neuritis. About 210 adults aged 18 to 50 will receive either privosegtor or a placebo, both alongside standard steroid treatment. The ma…
Phase: PHASE3 • Sponsor: Oculis • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New immunotherapy MK-1045 takes on tough lymphomas
Disease control Recruiting nowThis study tests an experimental immunotherapy called MK-1045 in 200 people with two types of non-Hodgkin lymphoma: follicular lymphoma (slow-growing) and diffuse large B-cell lymphoma (fast-growing). Participants have already tried at least two other treatments without success. …
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill aims to calm lupus skin flares in major trial
Disease control Recruiting nowThis study tests an experimental pill called enpatoran for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly redu…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for Hard-to-Treat myeloma? early trial of ABBV-438 begins
Disease control Recruiting nowThis early-stage trial tests an investigational drug called ABBV-438 in about 127 adults with multiple myeloma that has come back or stopped responding to treatment. The study has two parts: first, finding a safe dose, then testing that dose in more people. The main goal is to ch…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New study tracks how well risankizumab tames ulcerative colitis in daily life
Disease control Recruiting nowThis study follows 200 adults in Japan with moderate to severe ulcerative colitis who are already prescribed risankizumab by their doctor. Researchers will track how well the drug controls symptoms like diarrhea and rectal bleeding over up to 156 weeks. The goal is to see if the …
Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for Tough-to-Treat myeloma: Two-Drug combo enters Late-Stage trial
Disease control Recruiting nowThis study tests a new drug called elranatamab, alone or with another drug (daratumumab), against a standard three-drug combo for people with multiple myeloma that came back or didn't respond after at least one prior treatment. About 944 participants will be randomly assigned to …
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Free veggies and cooking classes aim to tame diabetes in pregnancy
Disease control Recruiting nowThis study tests a program that delivers fresh produce to the homes of pregnant women with type 1 or 2 diabetes who also struggle to afford healthy food. Participants also get group classes on diabetes, nutrition, and cooking, plus help finding other resources. The goal is to see…
Phase: NA • Sponsor: Ohio State University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for Hard-to-Treat myeloma: early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called RO7851624 in 160 people with relapsed/refractory multiple myeloma who have tried several standard treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that the dr…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New study tracks Ravulizumab's impact on daily life in myasthenia gravis
Disease control Recruiting nowThis observational study follows 50 adults with generalized myasthenia gravis who are new to complement inhibitors and are receiving ravulizumab (Ultomiris) in Poland. Researchers will track changes in daily living activities and other symptoms over time. The goal is to see how w…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New shot could ease daily struggles for myasthenia gravis patients
Disease control Recruiting nowThis study tests a new drug called B007 in 104 people with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive either B007 or a placebo as a shot under the skin twice a month. The goal is to see if B007 improves daily activities, like walk…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Engineered immune cells take on multiple sclerosis and other nerve diseases
Disease control Recruiting nowThis early-phase trial is testing a new treatment called KITE-363 for people with certain autoimmune nerve diseases that have not responded to standard therapies. KITE-363 is a type of CAR T-cell therapy that uses a patient's own immune cells, modified to target and attack faulty…
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for tough leukemia: MK-1045 takes on standard therapy
Disease control Recruiting nowThis study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new pill boost the power of an existing leukemia treatment?
Disease control Recruiting nowThis trial is testing whether an experimental drug called PBSS1113, taken as a pill alongside the standard medicine azacitidine, can help people with acute myeloid leukemia (AML) or a related condition called myelodysplastic syndrome (MDS). The study includes adults who have eith…
Phase: PHASE1, PHASE2 • Sponsor: Chaser Therapeutics, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Psoriasis drug may be safe for patients with fatty liver
Disease control Recruiting nowThis study looks at how long adults with plaque psoriasis and a common liver condition called MASLD (fatty liver disease) continue taking the drug secukinumab. Researchers will review medical records from several Spanish hospitals to track treatment duration and changes in liver …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for lymphoma patients: targeted drug combo aims to delay cancer return
Disease control Recruiting nowThis study tests whether adding the targeted drug zilovertamab vedotin to standard chemotherapy (R-CHP) helps people with untreated diffuse large B-cell lymphoma live longer without their cancer growing or spreading, compared to the current standard treatment (R-CHOP). About 1,04…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill hopes to tame rare childhood brain diseases
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called nizubaglustat (AZ-3102) in people aged 4 and older with Niemann-Pick type C disease, GM1 gangliosidosis, or GM2 gangliosidosis. The study lasts 18 months and compares the drug to a placebo to see if it is safe and can slow disease prog…
Phase: PHASE3 • Sponsor: Azafaros B.V. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Promising lupus drug anifrolumab now tested in kids
Disease control Recruiting nowThis phase 3 study tests anifrolumab, a biologic drug given by IV, in 100 children aged 5 to 18 with moderate to severe systemic lupus erythematosus (SLE). Participants continue their standard care and are randomly assigned to receive anifrolumab or a placebo. The goal is to see …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug avacopan under Long-Term safety review for vasculitis patients
Disease control Recruiting nowThis study is checking the long-term safety of a drug called avacopan for people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. About 300 adults who need treatment for a new diagnosis or flare-up will take avacopan or a placebo. The…
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill aims to keep blood cancer away after transplant
Disease control Recruiting nowThis study tests a daily pill called olutasidenib given after a stem cell transplant to people with certain blood cancers (like AML or MDS) that have an IDH1 mutation. The goal is to see if the drug is safe and tolerable as maintenance therapy. About 31 participants will take the…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug shows promise for severe eczema in toddlers
Disease control Recruiting nowThis study tests a drug called nemolizumab in toddlers aged 6 to 23 months with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams or ointments. The goal is to see how the drug moves through the body, if it is safe, and if it helps control the conditio…
Phase: PHASE2 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could a gut microbiome transplant ease axial spondyloarthritis?
Disease control Recruiting nowThis trial tests whether transferring gut bacteria from a healthy donor (fecal microbiota transplantation, or FMT) can reduce disease activity in people with axial spondyloarthritis (axSpA) who haven't fully responded to biologic therapy. Participants receive a single enema with …
Phase: PHASE2 • Sponsor: University Hospital of North Norway • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for kids with severe gut disease: drug trial launches
Disease control Recruiting nowThis study tests a new medicine called afimkibart in children aged 2 to 17 with moderate to severe ulcerative colitis, a disease that causes inflammation and sores in the colon. The goal is to see if the drug can safely help children feel better and achieve remission (no symptoms…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new pill bring back skin color in vitiligo?
Disease control Recruiting nowThis study tests a drug called zasocitinib in adults with nonsegmental vitiligo, an autoimmune condition that causes white patches on the skin. About 200 participants will take either the drug or a placebo for up to a year. The main goal is to see if the drug can improve skin col…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
MS patients may soon swap IV drips for quick shots
Disease control Recruiting nowThis Phase 3 trial tests whether a simple injection of frexalimab every 4 weeks works as well as the standard IV infusion for adults with relapsing or non-active progressive multiple sclerosis. About 160 participants will be randomly assigned to one of the two methods. The study …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
HIV patients to keep receiving promising treatments in new study
Disease control Recruiting nowThis study offers continued access to HIV medications (fostemsavir or dolutegravir/lamivudine) for 183 people who completed earlier ViiV Healthcare studies and are still benefiting. The goal is to provide treatment while collecting more safety information. Participants must have …
Phase: PHASE3 • Sponsor: ViiV Healthcare • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New antibody combo aims to outsmart Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase 3 trial tests an experimental drug, odronextamab, combined with lenalidomide in people with follicular or marginal zone lymphoma that has returned or not responded to treatment. The study first checks safety and dosing, then compares the new combo against the standard …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Experimental drug triapine paired with radiation targets recurrent brain cancers
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of the drug triapine when given together with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine works by blocking enzymes that cancer cells need to grow, while radiation kills cancer cells …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New combo aims to tame side effects in Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a new drug combination (glofitamab plus gemcitabine and oxaliplatin) in about 100 people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if a better steroid plan can reduce a serious side effect called …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New shot shows promise against tough blood cancer
Disease control Recruiting nowThis study tests a new drug called elranatamab for people with multiple myeloma that has returned or stopped responding to treatment. Half of the 492 participants will get elranatamab as a weekly shot; the other half will get one of several standard drug combinations. The goal is…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill combo takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called galvokimig in 160 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if different doses can reduce skin redness, itching, and rash better than a placebo. Participants will receive injections and be monitored for 16…
Phase: PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for myeloma patients: drug combo aims to keep cancer at bay
Disease control Recruiting nowThis study tests whether adding the experimental drug cevostamab to standard medications (pomalidomide and dexamethasone) works better than current treatments for multiple myeloma. About 380 adults whose cancer came back after 1 to 3 prior therapies will take part. The goal is to…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New targeted therapy aims to beat back childhood leukemia relapse
Disease control Recruiting nowThis study tests a drug called inotuzumab ozogamicin (Besponsa) against standard chemotherapy for children aged 1 to 17 with high-risk B-cell acute lymphoblastic leukemia that has returned after initial treatment. The goal is to see if the targeted drug can clear more cancer cell…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could a stem cell transplant tame tough scleroderma?
Disease control Recruiting nowThis study tests a stem cell transplant using the patient's own blood cells to treat severe scleroderma (systemic sclerosis) that hasn't improved with standard drugs. The goal is to see if this high-dose therapy is safe and can stop the disease from getting worse. The trial enrol…
Phase: PHASE2 • Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for CLL patients with weak hearts: acalabrutinib under the microscope
Disease control Recruiting nowThis study tests the drug acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have moderate to severe heart failure. Researchers want to see if acalabrutinib causes fewer heart-related side effects compared to other standard treatments. About 60 adults will t…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New study tests switch from IV to At-Home shots for gut disease
Disease control Recruiting nowThis study is testing the drug vedolizumab (Entyvio) in 400 adults with moderate to severe ulcerative colitis or Crohn's disease. Participants first receive the drug through an IV for 6 weeks, then switch to injections under the skin for the rest of the year. The main goal is to …
Phase: PHASE4 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New immunotherapy duo aims to outdo chemo for common lymphoma
Disease control Recruiting nowThis large phase 2/3 trial is testing whether a new immunotherapy drug called MK-1045, when combined with the targeted therapy rituximab, can treat follicular lymphoma better than the current standard of rituximab plus chemotherapy. About 960 people with previously untreated foll…
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for kids with colitis: risankizumab trial launches
Disease control Recruiting nowThis phase 3 study tests the drug risankizumab in about 120 children aged 2 to 18 with moderate to severe ulcerative colitis. The trial has three parts: an initial 12-week IV treatment period, a 52-week maintenance phase where patients get one of two doses by injection, and a lon…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill could help control blood disorder when standard drugs fail
Disease control Recruiting nowThis study tests a new drug called flonoltinib maleate in 60 people with polycythemia vera (a condition where the body makes too many red blood cells) who cannot take or no longer respond to standard treatments. The goal is to see if the drug safely reduces red blood cell levels …
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New combo aims to wipe out hidden myeloma cells after transplant
Disease control Recruiting nowThis study tests whether adding belantamab mafodotin to lenalidomide after a stem cell transplant can turn residual myeloma cells undetectable in patients with newly diagnosed multiple myeloma. About 94 adults who have already had a transplant will receive the combination therapy…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug offers hope for lymphoma patients who Can't get transplants
Disease control Recruiting nowThis phase 2 study tests the drug epcoritamab in 30 people with relapsed or refractory large B-cell lymphoma who are not eligible for a stem cell transplant. Epcoritamab is a bispecific antibody that helps the immune system target and kill cancer cells. The main goal is to see ho…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for hard-to-treat lymphoma: experimental drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests whether a new drug called SCTB35, combined with standard chemotherapy, works better than the current standard treatment (rituximab plus chemo) for people whose diffuse large B-cell lymphoma has come back or stopped responding to prior therapy. About 101 adults ag…
Phase: PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New pill aims to shrink spleen in bone marrow cancer
Disease control Recruiting nowThis phase 3 trial tests a new drug called flonoltinib maleate in people with intermediate- or high-risk myelofibrosis, a type of bone marrow cancer. The study compares flonoltinib to an existing drug, ruxolitinib, to see if it can reduce spleen size and improve symptoms. About 1…
Phase: PHASE3 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a drug calm severe eczema itch when the rash is mild? a new study investigates
Disease control Recruiting nowThis study looks at teenagers aged 12 to 17 who have severe atopic dermatitis (eczema) with intense itching but only a mild to moderate rash. They are being treated with dupilumab (Dupixent), a standard medication. The goal is to see how well dupilumab controls itching, improves …
Sponsor: Sanofi • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New 5-Drug combo aims to tackle tough lymphoma
Disease control Recruiting nowThis study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New antibody cocktail takes on tough lupus kidney disease
Disease control Recruiting nowThis early-stage trial is testing two experimental drugs, vonsetamig and odronextamab, in people with lupus nephritis that has not responded to standard treatments. The main goal is to check safety and side effects over the long term. Researchers will also see if the drugs can he…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug mosunetuzumab takes on standard therapy in lymphoma trial
Disease control Recruiting nowThis phase 3 trial tests whether mosunetuzumab works better than rituximab for people with a slow-growing type of lymphoma that has not spread much. Both drugs are lab-made antibodies that help the immune system attack cancer cells. About 600 adults with low tumor burden follicul…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Gene-Editing breakthrough aims to fix immune cells in rare disease
Disease control Recruiting nowThis early-stage trial tests a new gene-editing approach for X-linked chronic granulomatous disease (X-CGD), a rare immune disorder. Researchers will collect stem cells from 10 adult male participants, use base editing to correct the genetic mutation, and return the cells after m…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New inhaled insulin combo aims to simplify diabetes care for teens
Disease control Recruiting nowThis study tests a new approach for teens (ages 10-17) recently diagnosed with type 1 diabetes. They will use an inhaled insulin called Afrezza along with a long-acting injected insulin. The goal is to see if this combination helps keep blood sugar in a healthy range and is safe …
Phase: PHASE2 • Sponsor: Mannkind Corporation • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
MS patients may soon get a simpler shot option
Disease control Recruiting nowThis study looks at whether people with multiple sclerosis can safely switch from their current anti-CD20 therapy to a new under-the-skin version of ocrelizumab. About 100 participants will be followed for up to 48 weeks to see if brain lesions stay stable and if they are satisfi…
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New pill takes on hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests an experimental drug called EXS73565 in about 50 adults with certain blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, while also seeing if the d…
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for myelofibrosis patients who failed standard therapy
Disease control Recruiting nowThis study tests an experimental drug called flonoltinib maleate in about 64 people with a rare bone marrow cancer (myelofibrosis) that is moderate to high risk and has not responded to or stopped responding to standard JAK inhibitor therapy. Participants take a daily pill on an …
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Should High-Risk CLL patients start treatment early? major trial aims to find out
Disease control Recruiting nowThis phase 3 trial compares starting treatment with venetoclax and obinutuzumab right away versus waiting until symptoms appear in people with newly diagnosed, high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. About 247 participants will be randomly assigned t…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Engineered t cells target hidden leukemia cells in new trial
Disease control Recruiting nowThis phase I trial tests a new treatment for adults with acute myeloid leukemia (AML) who have minimal residual disease (MRD) — small amounts of cancer cells that remain after standard therapy. The treatment uses the patient's own T cells, genetically modified to recognize a prot…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New Two-Drug combo aims to beat back returning myeloma
Disease control Recruiting nowThis study compares a new combination of teclistamab and pomalidomide against the standard treatment (carfilzomib, pomalidomide, and dexamethasone) for multiple myeloma that has come back after improvement. About 162 adults with relapsed or refractory myeloma will take part. The …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New gene therapy offers hope for older kids and adults with 'bubble boy' disease
Disease control Recruiting nowThis study tests a gene therapy for people aged 2 to 50 with X-linked severe combined immunodeficiency (SCID-X1), a condition that leaves them without a working immune system. Participants receive their own blood stem cells that are genetically corrected in a lab, then infused ba…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New eczema drug TRB-061 enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called TRB-061 in healthy adults and people with moderate-to-severe atopic dermatitis (eczema). The study checks for safety, side effects, and how the drug moves through the body. Participants receive either TRB-061 or a placebo as injectio…
Phase: PHASE1 • Sponsor: TRex Bio, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Hard-to-Treat lymphoma: experimental drug surovatamig enters phase 2 trial
Disease control Recruiting nowThis Phase 2 trial is testing an investigational drug called surovatamig (AZD0486) in adults with relapsed or refractory B-cell non-Hodgkin lymphoma, including follicular lymphoma and large B-cell lymphoma. Participants must have tried at least two prior treatments. The study aim…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Engineered immune cells take on rare Muscle-Weakening disease
Disease control Recruiting nowThis early-stage study tests a new treatment called CABA-201 for people with generalized myasthenia gravis, a condition that causes severe muscle weakness. The therapy uses a patient's own immune cells, modified to target and destroy faulty immune cells that attack the body. The …
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
A glucose Monitor's second chance: can it tame type 1 diabetes in High-Risk teens?
Disease control Recruiting nowThis pilot study tests whether intermittent use of a continuous glucose monitor (CGM), along with regular medical visits, diabetes education, and psychological support, can improve blood sugar control in children and adolescents with high-risk type 1 diabetes in the Dominican Rep…
Sponsor: Life for a Child Program, Diabetes Australia • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New pill could slow MS disability in major trial
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called orelabrutinib against a placebo in about 990 people with non-active secondary progressive multiple sclerosis (MS). The goal is to see if the drug can delay worsening disability over 24 to 60 months. Participants are randomly assigned t…
Phase: PHASE3 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug aims to tame rare blood vessel disease
Disease control Recruiting nowThis Phase 3 trial is testing whether adding BDB-001 to standard treatments (cyclophosphamide, azathioprine, rituximab, or prednisone) helps more people with ANCA-associated vasculitis achieve remission. The study plans to enroll 300 adults with active GPA or MPA. Participants wi…
Phase: PHASE3 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New pill could transform leukemia treatment, phase 3 trial begins
Disease control Recruiting nowThis study tests a new oral drug, QTX-2101, combined with standard ATRA therapy for adults newly diagnosed with a low-risk form of acute promyelocytic leukemia (APL). The goal is to see if the oral capsule works as well as the current intravenous treatment. About 150 participants…
Phase: PHASE3 • Sponsor: Quetzal Therapeutics • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for rare leukemia: targeted pill tackles relapse
Disease control Recruiting nowThis study tests a pill called venetoclax for people whose hairy cell leukemia has returned after prior treatment. The drug blocks a protein that cancer cells need to survive. About 20 adults will take venetoclax to see if it shrinks tumors and improves blood counts, with the goa…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a tiny glucagon shot before workout stop blood sugar crashes in type 1 diabetes?
Disease control Recruiting nowThis study tests whether a low dose of glucagon, given before exercise, can prevent blood sugar drops in adults with type 1 diabetes who use an automated insulin pump. Eighteen participants will exercise after a meal, comparing glucagon to a standard glucose drink. The goal is to…
Phase: PHASE4 • Sponsor: Steno Diabetes Center Copenhagen • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo aims to boost immune attack on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase trial tests whether adding an experimental drug called SX-682 to a standard three-drug regimen is safe for people with multiple myeloma that has relapsed or become resistant. SX-682 works by freeing up immune cells to better kill cancer cells. The study will enro…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New MS drug candidate enters early safety testing
Disease control Recruiting nowThis early-stage study is testing a new drug called RO7121932 in 129 people with multiple sclerosis (MS). The goal is to check if the drug is safe and how the body handles it when given as a single or multiple doses, either through a vein or under the skin. Participants are not o…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New pill could shrink spleen and lymph nodes in rare ALPS disease
Disease control Recruiting nowThis study tests a drug called soquelitinib in 15 people aged 16 and older with autoimmune lymphoproliferative syndrome (ALPS). The goal is to see if the drug can shrink an enlarged spleen or lymph nodes and improve low blood cell counts. Participants take the pill twice daily fo…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo aims for deeper remission in older leukemia patients
Disease control Recruiting nowThis phase II trial tests whether adding gilteritinib to the usual two-drug therapy (azacitidine and venetoclax) can help older or frail adults with a specific type of acute myeloid leukemia (FLT3-mutated) achieve deeper remission. About 147 participants will be randomly assigned…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo aims to tame tough Crohn's
Disease control Recruiting nowThis study tests if the drug vorinostat is safe and can help people with moderate-to-severe Crohn's disease by reducing gut inflammation. Participants who respond well may then receive a maintenance treatment with ustekinumab for up to two years. The goal is to control symptoms a…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for leukemia patients: targeted therapy aims to eliminate hidden cancer cells
Disease control Recruiting nowThis study tests whether a targeted drug called gemtuzumab ozogamicin can clear tiny amounts of leukemia that remain after initial treatment in adults with acute myeloid leukemia (AML). The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a chem…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Tough-to-Treat leukemia: multiple drug cocktails tested
Disease control Recruiting nowThis phase II trial tests several experimental drug combinations against the standard treatment for high-risk acute myeloid leukemia (AML) in patients aged 59 or younger. The goal is to see if newer regimens, including venetoclax and liposome formulations, can better shrink cance…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Tough-to-Treat lymphoma: experimental drug combo enters phase 3 trial
Disease control Recruiting nowThis Phase 3 trial tests whether a new drug called SCTB35, combined with lenalidomide, works better than the standard rituximab-plus-lenalidomide combo for people with follicular lymphoma that has returned or not responded to treatment. About 93 adults aged 18-80 will take part. …
Phase: PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a targeted pill boost lymphoma cure rates?
Disease control Recruiting nowThis phase 2 trial is testing whether adding the drug acalabrutinib to standard chemotherapy and rituximab can improve cure rates for people with untreated diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma. About 132 adults with aggressive B-cell lymphom…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
HIV cocktail aims to free patients from daily pills
Disease control Recruiting nowThis phase 2 trial tests whether a mix of intensified antiretrovirals, a latency-reversing drug, an anti-proliferative drug, and a personalized vaccine can shrink the hidden HIV reservoir enough to allow people to stop their daily medication. The study will enroll 70 adults with …
Phase: PHASE2 • Sponsor: Federal University of São Paulo • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can engineered immune cells tame autoimmune disease?
Disease control Recruiting nowThis early-phase trial is testing whether a single infusion of engineered immune cells, called CAR NK cells, can safely and effectively treat people with moderate to severe autoimmune diseases that have not improved with standard treatment. The study will enroll 15 adults and wil…
Phase: EARLY_PHASE1 • Sponsor: YANRU WANG • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
Disease control Recruiting nowThis phase 2 trial is testing whether adding tafasitamab to the standard combination of lenalidomide and rituximab can improve complete responses in people with untreated follicular lymphoma or marginal zone lymphoma. Participants receive the three-drug regimen for about a year, …
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New CAR T-Cell therapy aims to stop High-Risk leukemia from returning
Disease control Recruiting nowThis Phase 2 trial is testing whether a CAR T-cell therapy called obecabtagene autoleucel (obe-cel) can help control newly diagnosed, high-risk B-cell acute lymphoblastic leukemia (ALL) after initial treatment. The study will enroll 30 adults with high-risk features who are in fi…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a diabetes drug protect blood vessels in type 1 diabetes?
Disease control Recruiting nowThis phase 2 trial tests whether dulaglutide, a drug used for type 2 diabetes, can improve small blood vessel function in adults with type 1 diabetes. The study involves 47 participants aged 18-40 with long-standing type 1 diabetes. Researchers measure blood flow and insulin sens…
Phase: PHASE2 • Sponsor: AdventHealth Translational Research Institute • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug aims to cut blood transfusions for bone marrow disease patients
Disease control Recruiting nowThis study tests an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome (MDS) who also have anemia. The goal is to see if the drug can reduce the need for blood transfusions and increase red blood cell levels. The study is in earl…
Phase: PHASE1, PHASE2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Double drug attack on ulcerative colitis shows promise
Disease control Recruiting nowThis study tests whether combining two drugs—vedolizumab and tofacitinib—can quickly bring moderate to severe ulcerative colitis under control. About 65 adults will receive both drugs for 8 weeks, and those who respond will continue on vedolizumab alone for nearly a year. The goa…
Phase: PHASE4 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New Two-Drug attack on Hard-to-Treat myeloma enters early human tests
Disease control Recruiting nowThis early-phase trial is testing a new combination of two drugs—cemsidomide (a pill) and elranatamab (a shot)—in about 60 people whose multiple myeloma has come back after prior treatments. The main goal is to see if the combination is safe and to find the best dose. Researchers…
Phase: PHASE1 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New weekly shot aims to tame Sjögren's Flare-Ups
Disease control Recruiting nowThis study tests an experimental drug called IMVT-1402 in 180 adults with moderate to severe Sjögren's disease. Participants receive either the drug or a placebo as a weekly injection under the skin for 24 weeks. The goal is to see if the drug can reduce overall disease activity …
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug combo trial targets blood cancers
Disease control Recruiting nowThis study tests a new drug called AZD0486, alone or with other cancer drugs, in people with B-cell blood cancers like certain lymphomas and leukemias. The goal is to see if it is safe and helps shrink or control the cancer. About 408 adults will take part in this early-phase tri…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New combo attack on tough lymphoma: two immune therapies join forces
Disease control Recruiting nowThis phase 2 trial is testing a combination of two immune-based therapies—axicabtagene ciloleucel (a CAR T-cell therapy) and glofitamab (a bispecific antibody)—in 40 people with large B cell lymphoma that has relapsed or not responded to first treatment. The goal is to see if the…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can engineered immune cells tame a debilitating autoimmune disease?
Disease control Recruiting nowThis phase 1 trial is testing an experimental therapy called SYS6020 for people with refractory generalized myasthenia gravis, a chronic autoimmune condition that causes severe muscle weakness. SYS6020 uses a patient's own immune cells, engineered to target BCMA, a protein involv…
Phase: PHASE1 • Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Immune booster shot aims to speed recovery after cord blood transplant
Disease control Recruiting nowThis early-phase trial tests whether injecting special immune progenitor cells (HTLPs) can help the immune system recover faster after a cord blood transplant in adults with blood cancers. Ten participants will receive the injection alongside their transplant. The goal is to see …
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Old malaria drug may tame lupus skin flares
Disease control Recruiting nowThis study tests whether quinacrine, a medication originally used for malaria, can safely reduce skin rashes and sores in people with cutaneous lupus erythematosus (CLE). Participants receive either quinacrine or a placebo for 12 weeks, then all receive quinacrine for another 12 …
Phase: PHASE2 • Sponsor: Victoria Werth • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for tough leukemia? early trial of debio 1562M begins
Disease control Recruiting nowThis early-phase trial is testing a new drug called Debio 1562M in about 134 people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The study first checks safety and finds the right dose, then looks at whether the drug can shrink the can…
Phase: PHASE1, PHASE2 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Recruiting nowThis study tests a new treatment called AZD0120 for people with severe lupus that hasn't improved with standard therapies. AZD0120 is a type of CAR T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to calm the overactive immune system. The trial will enroll…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis phase 2 trial tests the drug mosunetuzumab in 30 people with chronic lymphocytic leukemia (CLL) who still have detectable cancer cells after at least six months of standard therapy. The goal is to see if the drug can clear those remaining cells and improve outcomes. Particip…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug aims to shield autoimmune patients from Life-Threatening infections
Disease control Recruiting nowThis study tests whether a medicine called Panzyga can prevent major infections in people with autoimmune or rheumatic conditions who have low antibody levels after receiving B-cell depletion therapy. About 360 adults will receive either Panzyga or a placebo, and researchers will…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Three-Drug combo quiet lupus kidney flares?
Disease control Recruiting nowThis trial tests whether adding voclosporin to standard lupus nephritis treatment (mycophenolate mofetil and prednisolone) reduces kidney inflammation faster and more completely than standard treatment alone. Adults with active lupus nephritis will be randomly assigned to either …
Phase: PHASE4 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New antibody drug targets skin scarring in transplant survivors
Disease control Recruiting nowThis study tests a drug called axatilimab for people whose skin becomes thick and hard (sclerotic) after a donor stem cell transplant, a condition called chronic graft-versus-host disease. The drug aims to block immune signals that cause inflammation and scarring. About 50 adults…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New combo therapy aims to tackle Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests whether adding a targeted drug (nemtabrutinib) to a personalized cell therapy (lisocabtagene maraleucel) can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to treatment. About 20 adults will rec…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New shot could help tame stubborn Graves' disease
Disease control Recruiting nowThis study tests a drug called efgartigimod, given as a shot under the skin, for adults with Graves' disease whose thyroid levels are still too high despite taking standard antithyroid drugs. About 230 people will take part, and some will get the drug while others get a placebo. …
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New breathing machine approach aims to shield heart in lung failure patients
Disease control Recruiting nowThis study tests a breathing machine strategy that adjusts pressure based on lung measurements to protect the right side of the heart in 180 adults with moderate to severe lung failure from pneumonia. The goal is to see if this method reduces heart strain and complications compar…
Phase: NA • Sponsor: Beijing Chao Yang Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug aims to tame overactive thyroid without lifelong pills
Disease control Recruiting nowThis trial tests a new drug called IMVT-1402 for adults with Graves' disease, a condition where the thyroid is overactive. The study will include 210 participants who still have high thyroid levels despite taking standard medications. Participants will receive either one of two d…
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a pill tame muscle weakness in myasthenia gravis?
Disease control Recruiting nowThis phase 3 trial is testing a new oral form of cladribine, a drug that calms the immune system, in 264 adults with generalized myasthenia gravis. Participants receive either low-dose cladribine, high-dose cladribine, or a placebo in two courses four weeks apart. The main goal i…
Phase: PHASE3 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests whether IMG-007 can safely reduce eczema symptoms like itching and redness in adults with moderate-to-severe disease who haven't responded well to topical treatments. About 405 participants will receive either the drug or a placebo, and researchers will measure s…
Phase: PHASE2 • Sponsor: Inmagene LLC • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for teens with rare bleeding disorder: experimental drug enters final testing
Disease control Recruiting nowThis study tests an IV drug called efgartigimod in teens aged 12 to 18 with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet counts…
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema). About 280 participants will receive either the drug or a placebo to see if it reduces skin redness, thickness, and itching over 24 weeks. The goal is to find a saf…
Phase: PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for psoriatic arthritis sufferers: experimental drug sonelokimab enters final testing phase
Disease control Recruiting nowThis study tests a new drug called sonelokimab for adults with active psoriatic arthritis who have not improved with or cannot take standard TNF-blocker medications. About 600 participants will receive either sonelokimab, a placebo, or an existing drug (risankizumab) for comparis…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill aims to break the cycle of repeat c. diff infections
Disease control Recruiting nowThis phase 2 trial tests an oral drug called ibezapolstat in 20 people who have had three or more C. diff infections in the past year. The goal is to see if the drug can cure the current infection and reduce the chance of it coming back. Participants will take the drug twice a da…
Phase: PHASE2 • Sponsor: Acurx Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new shoulder implant restore Pain-Free movement?
Disease control Recruiting nowThis study follows 60 adults who receive a total shoulder replacement using the PRIMA humeral stem, either in an anatomic or reverse configuration. The goal is to measure changes in shoulder function, pain, and quality of life over 24 months, as well as how well the implant holds…
Sponsor: Limacorporate S.p.a • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cocktail targets Hard-to-Treat leukemia
Disease control Recruiting nowThis early-phase trial tests whether combining three drugs—ruxolitinib, cladribine, and venetoclax—can control T-cell prolymphocytic leukemia (T-PLL) that has returned or not responded to prior treatment. The study will enroll 36 adults and primarily monitor safety and side effec…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Double-Drug attack on Crohn's: could two biologics be better than one?
Disease control Recruiting nowThis study is testing whether combining two different biologic drugs can better control moderate to severe Crohn's disease. One hundred adults will first receive either vedolizumab plus adalimumab or vedolizumab plus ustekinumab. Those who respond well will then switch to vedoliz…
Phase: PHASE4 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug cocktail aims to beat back tough blood cancers in young patients
Disease control Recruiting nowThis early-phase study tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) for teens and young adults aged 12 to 30 whose T-cell acute lymphoblastic leukemia or lymphoma has returned or not responded to prior treatment. The main goal is to c…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Old drug, new hope: niclosamide tested for tough childhood leukemia
Disease control Recruiting nowThis early-phase trial tests niclosamide, a drug previously used for tapeworm infections, combined with standard chemotherapy in 16 children whose acute myeloid leukemia (AML) has returned or not responded to treatment. The main goal is to find a safe dose and check for side effe…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug trial aims to tame gut disease in kids
Disease control Recruiting nowThis study tests a daily pill called filgotinib in 80 children aged 8 to 17 with moderate to severe ulcerative colitis, a chronic gut disease. The goal is to see if the drug can reduce inflammation and help children feel better. All participants receive the drug, and the study tr…
Phase: PHASE3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can learning to cope boost Crohn's treatment? new trial aims to find out
Disease control Recruiting nowThis study tests whether adding a structured coping skills program to standard biologic medication improves emotional well-being and disease remission in people with early Crohn's disease. 170 adults with active Crohn's for less than 5 years will receive either the coping program…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New CML drug asciminib under Real-World study
Disease control Recruiting nowThis study is watching how well asciminib works and how safe it is in adults with a type of blood cancer called chronic myeloid leukemia. It includes people who are newly diagnosed or have already tried one other treatment. The main goal is to see how many patients reach a very l…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Smart insulin system aims to protect moms and babies in diabetes pregnancy
Disease control Recruiting nowThis study tests whether an automated insulin delivery system (CamAPS FX) can help women with type 1 diabetes maintain better blood sugar control before and during pregnancy, compared to their usual insulin routine. The trial will enroll 305 women aged 18-45 who are either planni…
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cell therapy HN2301 enters human trials for autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new therapy, HN2301, in 30 adults with lupus, scleroderma, or rheumatoid arthritis. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the treatment helps control the disease by measuring immune…
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New injection aims to boost platelets in ITP patients
Disease control Recruiting nowThis early-phase trial tests a new drug called STSA-1301, given as an injection under the skin, for people with immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets, raising bleeding risk. The study will first check safety in healthy volunteers, …
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu BioJeTay Biotechnology Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for rare thymic cancer: targeted drug trial launches
Disease control Recruiting nowThis phase 2 trial tests a drug called sacituzumab tirumotecan (Sac-TMT) in 30 people with advanced thymic carcinoma that has worsened after platinum-based chemotherapy. Participants receive the drug every two weeks, and doctors will check how well it shrinks tumors and monitor s…
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug targets root cause of rare overgrowth syndromes
Disease control Recruiting nowThis Phase 2 study tests an oral drug called RLY-2608 in adults and children with overgrowth conditions (like CLOVES or Klippel-Trenaunay syndrome) caused by PIK3CA gene mutations. The drug is designed to block the faulty protein driving abnormal tissue growth. The trial will enr…
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Two-Drug combo tame a rare blood cancer?
Disease control Recruiting nowThis trial is testing whether combining two drugs, pacritinib and azacitidine, can help people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. The study includes adults who are newly diagnosed or have had limited prior treatment. The goal is to find the safest d…
Phase: PHASE1, PHASE2 • Sponsor: Douglas Tremblay • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can peer mentors help stop HIV transmission from mother to child?
Disease control Recruiting nowThis study tests an enhanced Mentor Mother strategy, where trained peer counselors provide tailored support to pregnant and postpartum women living with HIV. The goal is to see if this approach can be successfully implemented and improve health outcomes, such as keeping mothers i…
Phase: NA • Sponsor: Indiana University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a common amino acid outperform chemotherapy cream to restore skin color?
Disease control Recruiting nowThis trial tests whether applying tyrosine or 5-fluorouracil to the skin, combined with a fractional erbium YAG laser, can help restore color in people with focal vitiligo. Vitiligo is an autoimmune condition that causes white patches by destroying pigment-making cells. The study…
Phase: EARLY_PHASE1 • Sponsor: Aswan University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New wearable could double diabetes monitoring power
Disease control Recruiting nowThis study is testing a new wearable device that continuously measures both glucose (sugar) and ketone levels in adults with type 1 diabetes. The device is worn for 15 days and its readings are compared to standard lab tests. The goal is to see if it is accurate and safe enough f…
Phase: NA • Sponsor: Henan University of Science and Technology • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a pill reverse eye bulging in thyroid eye disease?
Disease control Recruiting nowThis clinical trial tests whether an oral medication called linsitinib can reduce eye bulging (proptosis) in people with moderate to severe active thyroid eye disease (TED). Participants will take either linsitinib or a placebo twice daily for 24 weeks. The main goal is to see if…
Phase: PHASE3 • Sponsor: Sling Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a drug combo replace chemo and transplant for multiple myeloma?
Disease control Recruiting nowThis study tests whether a combination of two drugs (elranatamab and lenalidomide) can replace high-dose chemotherapy and stem cell transplant for people newly diagnosed with multiple myeloma. About 824 adults under 70 will be randomly assigned to either standard treatment or the…
Phase: PHASE3 • Sponsor: Intergroupe Francophone du Myelome • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Experimental antibody takes aim at Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase trial tests a drug called teclistamab in 30 adults with plasmablastic lymphoma that has returned or not responded to prior treatment. Teclistamab is a bispecific antibody designed to attach to both cancer cells and immune T-cells, helping the immune system attack…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New oral drug shows promise for rare sun allergy conditions
Disease control Recruiting nowThis study is for people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain and skin reactions to sunlight. The purpose is to check the long-term safety of an oral medication called dersimelagon. About 301 participant…
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Weekly shot could replace daily growth hormone for kids
Disease control Recruiting nowThis phase 3 trial compares a once-weekly growth hormone injection (lonapegsomatropin) to a daily one (somatropin) in 186 prepubertal children with growth failure due to Turner syndrome, SHOX deficiency, being small for gestational age, or idiopathic short stature. The goal is to…
Phase: PHASE3 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New Tri-Specific antibody takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial tests a new drug called SIM0500 in 130 adults with multiple myeloma that has returned or stopped responding to treatment. SIM0500 is a tri-specific antibody designed to help the immune system attack cancer cells. The study will first find the safest dose, t…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Gut bacteria and minerals: a new hope for ulcerative colitis remission?
Disease control Recruiting nowThis trial is testing whether adding a Lactobacillus probiotic or a trace element supplement to standard ulcerative colitis treatment can help keep the disease in remission. About 132 adults with mild to moderate ulcerative colitis will be randomly assigned to one of three groups…
Phase: PHASE4 • Sponsor: National Hepatology & Tropical Medicine Research Institute • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug aims to tame overactive thyroid without daily pills
Disease control Recruiting nowThis phase 2b trial tests an experimental drug called IMVT-1402 in 240 adults with Graves' disease whose thyroid is still overactive despite standard treatment. The goal is to see if the drug can help patients achieve normal thyroid hormone levels and stop taking antithyroid medi…
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug CLN-978 tested for Sjogren's sufferers
Disease control Recruiting nowThis early-stage trial is testing a new drug called CLN-978 in 36 adults with active, moderate to severe Sjogren's disease. The main goal is to see if the drug is safe and tolerable, while also checking how it affects immune cells in the blood. Participants receive the drug as a …
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug combo aims to boost CAR-T success in hard-to-treat lymphoma
Disease control Recruiting nowThis study tests whether adding two oral medications (sonrotoclax and zanubrutinib) to standard CAR-T cell therapy can improve treatment results for people with mantle cell lymphoma that has come back or not responded to prior treatment. About 40 adults who are already eligible f…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New triple therapy aims to wipe out hidden CLL cells
Disease control Recruiting nowThis study tests a combination of three drugs (zanubrutinib, obinutuzumab, and sonrotoclax) in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the treatment can make the cancer undetectable in the bloo…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New injection shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for skin cancer patients with complex medical histories
Disease control Recruiting nowThis study tests a drug called cosibelimab in 80 people with advanced skin cancer who also have a kidney transplant or a blood cancer. The drug works by helping the immune system attack cancer cells. Researchers will check if the tumors shrink and monitor for side effects.
Phase: PHASE4 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New shot targets lymphoma without chemo
Disease control Recruiting nowThis phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with a slow-growing type of lymphoma that hasn't been treated yet. The drug works by helping the body's immune cells find and kill cancer cells. About 30 adults will receive up to 8 c…
Phase: PHASE2 • Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New pill could ease psoriatic arthritis pain in major trial
Disease control Recruiting nowThis Phase 3 trial tests whether the experimental drug zasocitinib (TAK-279) can reduce joint swelling and pain in people with active psoriatic arthritis. About 600 adults will receive either the drug or a placebo for up to 60 weeks. The main goal is to see if more people on the …
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New insulin pump system put to the test in 400-Person safety trial
Disease control Recruiting nowThis study is checking if a new insulin pump (NMX8) and continuous glucose monitor (DS5/Simplera Sync) are safe for people with type 1 or type 2 diabetes. About 400 participants, ages 7 to 85, will first wear the sensor for up to 40 days, then use the pump for about 90 days while…
Phase: NA • Sponsor: Medtronic MiniMed, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New combo therapy aims to beat back relapsed leukemia after transplant
Disease control Recruiting nowThis phase 2 trial tests whether combining interferon-gamma (a protein that boosts the immune system) with donor immune cells can help patients whose acute myeloid leukemia or myelodysplastic syndromes have returned after a stem cell transplant. The study will enroll 45 adults an…
Phase: PHASE2 • Sponsor: Sawa Ito, MD • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New combo therapy for rare blood cancers put on hold
Disease control Recruiting nowThis phase 2 trial compares a drug combo (ASTX727 plus iadademstat) against ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The study aims to see if adding iadademstat improves complete response rates. However, the trial …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a diabetes drug help fight opioid addiction?
Disease control Recruiting nowThis study tests whether tirzepatide, a drug used for diabetes and weight loss, can help people with moderate to severe opioid use disorder stay in treatment and use fewer opioids when added to their regular buprenorphine medication. About 310 adults who recently started buprenor…
Phase: PHASE2 • Sponsor: T. John Winhusen, PhD • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a targeted drug boost chemo success in leukemia?
Disease control Recruiting nowThis phase II trial is testing whether adding the drug venetoclax to standard chemotherapy can improve remission rates in younger patients with intermediate-risk acute myeloid leukemia (AML). About 153 participants will receive either standard chemo or a combination with venetocl…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Meals on wheels for diabetes: new study tests food delivery to fight hunger and improve health
Disease control Recruiting nowThis study tests whether a nutrition program that provides twice-daily meal delivery for up to 90 days after hospital discharge, plus diet education, can reduce food insecurity in people with type 1 or type 2 diabetes. About 160 hospitalized patients who screen positive for food …
Phase: NA • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Brain scans to reveal if new MS drug quietly calms inflammation
Disease control Recruiting nowThis study looks at whether the experimental drug remibrutinib can reduce inflammation in the brain and spinal cord of people with relapsing multiple sclerosis (MS). Participants, aged 40 to 70, will have PET scans, MRIs, and blood and spinal fluid samples taken before and six mo…
Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
CAR t cells aim to lock in remission for leukemia patients
Disease control Recruiting nowThis study tests a CAR T-cell therapy called obe-cel in adults with B-cell acute lymphoblastic leukemia (ALL) whose cancer is in complete remission with no detectable cancer cells. The goal is to see if obe-cel can prevent the cancer from coming back. About 40 participants will r…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a simple shot replace hospital stays for myeloma patients?
Disease control Recruiting nowThis study tests whether the drug elranatamab can be given safely in an outpatient clinic instead of the hospital for people with multiple myeloma that has come back or stopped responding to treatment. About 46 adults will receive the drug along with a single preventive dose of a…
Phase: PHASE2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a targeted drug boost transplant success for tough blood cancers?
Disease control Recruiting nowThis clinical trial is testing whether adding the drug venetoclax to standard chemotherapy before a stem cell transplant can improve outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study will enroll 324 participants and aims …
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New ointment aims to restore skin color in vitiligo
Disease control Recruiting nowThis Phase 3 trial tests whether an ointment called MH004 can help restore skin color in people with non-segmental vitiligo. The study includes adolescents and adults aged 12 to 75 with facial vitiligo. Participants apply the ointment twice daily for 24 weeks, and researchers mea…
Phase: PHASE3 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug rocbrutinib takes on pirtobrutinib in blood cancer showdown
Disease control Recruiting nowThis study tests a new drug, rocbrutinib, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding to treatment. All participants have already tried a type of BTK inh…
Phase: PHASE3 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New pill could clear psoriasis in teens
Disease control Recruiting nowThis study tests a daily pill called deucravacitinib in teenagers aged 12 to 18 with moderate to severe plaque psoriasis. About 366 participants will receive either the drug or a placebo. The main goals are to see if the drug improves skin clearance by at least 75% and reduces ov…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Blood test may spare throat cancer patients from full radiation
Disease control Recruiting nowThis trial is testing whether a blood test that detects HPV DNA can help doctors safely reduce the amount of radiation given after surgery for HPV-positive throat cancer. After surgery, patients with undetectable HPV DNA in their blood may receive a lower dose of radiation, while…
Phase: NA • Sponsor: Indiana University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Tailored therapy may save colons in severe ulcerative colitis
Disease control Recruiting nowThis trial is testing whether personalized, adaptive treatment strategies can help people hospitalized with acute severe ulcerative colitis. The approach adjusts medication based on how each patient responds, aiming to improve outcomes and reduce the need for colon removal. The s…
Phase: PHASE4 • Sponsor: Berinstein, Jeffrey • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New oral drug trial aims to tame MS in kids
Disease control Recruiting nowThis study tests an oral drug called fenebrutinib in 12 children and adolescents aged 10 to 17 with relapsing multiple sclerosis. The goal is to see how the drug moves through the body, how safe it is, and whether it reduces new brain lesions seen on MRI. Participants can choose …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a once-every-few-weeks IV infusion tame rheumatoid arthritis?
Disease control Recruiting nowThis study tests whether giving sarilumab (Kevzara) through an IV with longer intervals between doses is safe and works well for adults with moderate-to-severe rheumatoid arthritis. Participants receive the drug intravenously, with or without other standard arthritis medications.…
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New pill could ease psoriatic arthritis without biologics
Disease control Recruiting nowThis Phase 3 study tests whether the oral drug zasocitinib (TAK-279) can improve symptoms of active psoriatic arthritis in people who have never used biologic treatments. About 1,088 adults will receive either zasocitinib, an active comparator, or a placebo for up to 60 weeks. Th…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Targeting the immune system: a new antibody may free Graves' patients from daily drugs
Disease control Recruiting nowThis phase 2 trial tests whether felzartamab, an antibody that targets immune cells producing harmful antibodies, can restore normal thyroid function in people with Graves' disease. Participants will receive either felzartamab or a placebo alongside their usual anti-thyroid drugs…
Phase: PHASE2 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Genetically modified t cells take aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of immunotherapy for people with T-cell leukemia or lymphoma that has returned. The treatment involves taking a patient's own immune cells (or cells from a past stem cell donor), adding a special receptor that targets a protein called …
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug BBD-1 shows promise for painful skin and kidney disease
Disease control Recruiting nowThis study tests a new drug, BBD-1, against standard steroids for IgA vasculitis, a disease that causes purple spots on the skin, joint pain, and can damage the kidneys. The trial will enroll 30 adults with confirmed IgA vasculitis. The goal is to see if BBD-1 can clear skin spot…
Phase: PHASE2 • Sponsor: Qifeng Zhang • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New CAR T-Cell therapy aims to outperform current treatment for aggressive lymphoma
Disease control Recruiting nowThis phase 3 trial tests whether a new CAR T-cell therapy, KITE-753, works better than the current standard, axicabtagene ciloleucel (axi-cel), for adults with large B-cell lymphoma that returned or didn't respond to first treatment. About 550 participants will receive one infusi…
Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New antibody drug takes aim at rheumatoid arthritis in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called KT502 in 27 adults with moderate to severe rheumatoid arthritis. The drug is designed to deplete certain immune cells (B cells) that contribute to joint inflammation. The main goal is to check safety and find the right dose, not yet …
Phase: PHASE1 • Sponsor: Kali Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug aims to outperform chemo for common lymphoma
Disease control Recruiting nowThis phase 3 trial tests an experimental drug called odronextamab for people with previously untreated follicular lymphoma, a slow-growing blood cancer. The study compares odronextamab alone or with standard chemotherapy to see if it leads to better remission rates. About 822 par…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo aims to control rare blood cancer in High-Risk patients
Disease control Recruiting nowThis study tests a combination of two drugs, azacitidine and enasidenib, in people with a high-risk blood cancer called myelodysplastic syndrome (MDS) that has a specific genetic change (IDH2 mutation). The goal is to see if the drugs can stop cancer growth and improve outcomes. …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a tailored chemo cocktail outsmart a common leukemia?
Disease control Recruiting nowThis trial is testing whether a chemotherapy combination called HAD, given at intermediate doses, works better than the standard regimen for people with a specific genetic subtype of acute myeloid leukemia (AML) known as CEBPA double-mutated. The study enrolls adults aged 14 to 5…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a daily pill replace infusions for MS? new trial aims to find out
Disease control Recruiting nowThis phase 3 trial is testing whether a daily pill called remibrutinib works as well as the standard infusion or injection ocrelizumab for people with relapsing multiple sclerosis. About 360 adults aged 40–70 who are stable on ocrelizumab will either switch to remibrutinib or sta…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can diabetes drugs tame joint inflammation in psoriatic arthritis?
Disease control Recruiting nowThis trial asks whether GLP-1 medications, commonly used for type 2 diabetes and weight loss, can better control psoriatic arthritis symptoms than nutrition counseling alone. Adults with psoriatic arthritis who also have obesity and type 2 diabetes will be randomly assigned to re…
Phase: PHASE4 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can two common compounds supercharge CAR-T against myeloma?
Disease control Recruiting nowThis phase II trial at Mayo Clinic is testing whether adding dasatinib and quercetin to standard CAR-T therapy can improve outcomes for people with multiple myeloma that has returned or not responded to prior treatments. The study will enroll 44 adults who have already tried at l…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Diabetes drug tirzepatide tested for type 1 in new trial
Disease control Recruiting nowThis study tests whether tirzepatide, a drug used for type 2 diabetes, can help people with type 1 diabetes. Researchers will measure how the body responds to insulin and meals before and after 6 weeks of treatment. 44 adults with type 1 diabetes who use an automated insulin pump…
Phase: PHASE2 • Sponsor: Victor Chang Cardiac Research Institute • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug telitacicept aims to tame Sjögren's in major trial
Disease control Recruiting nowThis Phase 3 study tests whether telitacicept, a biologic drug given as a shot, can reduce disease activity in adults with active primary Sjögren's disease. About 250 participants will receive either telitacicept or a placebo for 48 weeks. The main goal is to see if the drug impr…
Phase: PHASE3 • Sponsor: Vor Biopharma • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New Antibody-Drug conjugate enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug tulisokibart aims to ease psoriatic arthritis pain
Disease control Recruiting nowThis study tests a new medicine called tulisokibart for people with active psoriatic arthritis, a condition causing joint pain and skin plaques. Researchers will compare different doses of the drug to a placebo in 140 adults to see if it improves symptoms like joint tenderness an…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New cocktail aims to tame rare brain cancer
Disease control Recruiting nowThis early-stage trial tests a combination of four drugs—lenalidomide, nivolumab, rituximab, and methotrexate—in people with primary CNS lymphoma, a rare cancer of the brain or spinal cord. The goal is to find the safest dose and see if adding lenalidomide and nivolumab to standa…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for kids with Crohn's: drug trial targets remission
Disease control Recruiting nowThis phase 3 trial tests a drug called afimkibart in 100 children aged 2-17 with moderate-to-severe Crohn's disease. The goal is to see if it can help children feel better and heal their intestines. Participants will receive the drug as an IV infusion or injection, and researcher…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can early MS patients pause treatment? new trial seeks answers
Disease control Recruiting nowThis study looks at whether people with early relapsing multiple sclerosis (MS) can stop taking ocrelizumab (Ocrevus) after two years without their disease coming back. All 123 participants will receive ocrelizumab for the first two years. Then, some will switch to a placebo whil…
Phase: PHASE4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug may reduce insulin shots for young diabetes patients
Disease control Recruiting nowThis study tests a drug called teplizumab in people aged 1 to 25 who were recently diagnosed with type 1 diabetes. The goal is to see if teplizumab can help control blood sugar and reduce the need for insulin at mealtimes. Participants will receive either teplizumab or a placebo …
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for rare blood cancer: QUANTUM trial tests targeted therapy after transplant
Disease control Recruiting nowThis study tests whether a new drug called teclistamab, given after standard treatment and a stem cell transplant, can help people with a rare and aggressive blood cancer called plasma cell leukemia live longer. About 74 participants will receive either standard follow-up therapy…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Stem cells may supercharge CAR t for tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing whether adding a patient's own blood stem cells to standard CAR T-cell therapy is safe and doable for people with relapsed or refractory blood cancers like lymphoma, leukemia, and myeloma. Twenty participants will receive their own stem cells 10 …
Phase: PHASE1 • Sponsor: Joshua Sasine, MD, PhD • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug HC-7366 tested for tough leukemia
Disease control Recruiting nowThis early-phase trial is testing a new drug called HC-7366 in 18 adults with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The main goal is to find a safe dose and check for side effects. Researchers hope this drug may offer a new option f…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for rare gut disease? drug trial launches for APECED enteritis
Disease control Recruiting nowThis phase 2 trial tests a drug called emapalumab in 10 people with APECED, a rare disease where the immune system attacks the body. The drug aims to reduce gut inflammation (enteritis) that causes severe symptoms. Participants receive 7 IV doses over 6 months, and researchers tr…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for blood cancer patients: experimental combo enters final testing phase
Disease control Recruiting nowThis study tests whether a new drug, sonrotoclax, combined with an antibody therapy works better than the current standard treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to prior therapy. About 630 par…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase study tests a new kind of CAR T-cell therapy for people with multiple myeloma that has come back or not responded to at least three prior treatments. The cells are 'armored' to resist a protein (TGF-beta) that normally blocks their attack. Up to 30 adults will re…
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a weekly pill replace daily HIV treatment? new study aims to find out.
Disease control Recruiting nowThis study tests whether a once-weekly combination of two experimental drugs (islatravir and ulonivirine) works as well as the standard daily three-drug pill Biktarvy for people newly diagnosed with HIV-1. About 570 adults who have never taken HIV medication will be randomly assi…
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Personalized cell therapy aims to tame type 1 diabetes in early trial
Disease control Recruiting nowThis early-stage study is testing a new treatment called GNTI-122 for adults who were recently diagnosed with type 1 diabetes. The therapy is made from a person's own blood cells and is designed to help rebalance the immune system. Sixteen participants will receive either a low o…
Phase: PHASE1 • Sponsor: GentiBio, Inc • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New CAR t-cell combo aims to control aggressive leukemia
Disease control Recruiting nowThis study tests a CAR T-cell drug called brexucabtagene autoleucel in 40 adults with B-cell acute lymphocytic leukemia that has come back or is hard to treat. Participants first receive standard chemotherapy drugs to reduce cancer, then get the CAR T-cells. The goal is to see if…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Less invasive breast cancer surgery could reduce lymphedema risk
Disease control Recruiting nowThis phase 2 trial is testing whether a less extensive lymph node surgery, called targeted axillary dissection (TAD), can safely control cancer in women aged 45 and older with early-stage ER+ breast cancer that has spread to lymph nodes detected by ultrasound. Participants will h…
Phase: PHASE2 • Sponsor: Alice Chung • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can online therapy stop insulin resistance in HIV patients? new trial aims to find out
Disease control Recruiting nowThis study tests whether an internet-based depression treatment called cognitive behavioral therapy (iCBT-D) can prevent insulin resistance from getting worse in adults with HIV who are on antiretroviral therapy and have depression. Researchers will compare the online therapy pro…
Phase: NA • Sponsor: Indiana University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a reshaped chemo combo tame lymphoma with fewer side effects?
Disease control Recruiting nowThis Phase 3 trial compares a modified version of the standard DHAP chemotherapy regimen against the original in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The modified regimen spreads out the cisplatin and cytarabine doses over several days, aiming…
Phase: PHASE3 • Sponsor: King Edward Medical University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for kids with tough leukemia: targeted drugs added to chemo
Disease control Recruiting nowThis study tests whether adding dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs alongsi…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug aims to tame immune system in lupus and Sjogren's
Disease control Recruiting nowThis early-stage trial tests an investigational drug called ABBV-319 in 36 adults with lupus or Sjogren's disease. The drug is designed to deplete overactive B cells, which are part of the immune system that cause inflammation and symptoms. Participants receive two doses by IV, 2…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Engineered cells take on hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new approach for people with certain blood cancers (like lymphoma) that have returned or not responded to standard therapy. Participants receive their own immune cells that have been modified to attack cancer cells, along with specially edited stem …
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New combo therapy aims to boost survival in adult leukemia
Disease control Recruiting nowThis study is testing a powerful chemotherapy regimen originally designed for children, combined with the targeted drug venetoclax and immunotherapy, in adults aged 14 to 60 with a certain type of acute lymphoblastic leukemia (ALL). The goal is to see if this approach can achieve…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo aims to keep high-risk myeloma in check
Disease control Recruiting nowThis study tests if the drug elranatamab, given before and after a stem cell transplant, can better control high-risk multiple myeloma. About 40 adults with newly diagnosed, high-risk disease will receive the drug to reduce cancer cells before transplant and then as maintenance t…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug cocktail aims to tackle tough blood cancers
Disease control Recruiting nowThis phase II trial is testing a combination of six chemotherapy drugs (clofarabine, etoposide, cyclophosphamide, liposomal vincristine, dexamethasone, and bortezomib) in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, or related cancers that have come back or…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New lupus drug candidate enters human safety testing
Disease control Recruiting nowThis early-stage study tests a new drug called IASO-782 in 20 adults with systemic lupus erythematosus (SLE). The main goal is to see if the drug is safe and tolerable. Participants will receive either the drug or a placebo, and researchers will monitor for side effects.
Phase: PHASE1 • Sponsor: Shanghai IASO Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo after brain radiation shows promise for lymphoma patients
Disease control Recruiting nowThis early-phase trial tests whether a combination of two drugs (loncastuximab tesirine and rituximab) given after precise radiation to the brain is safe and effective for central nervous system lymphoma. The study enrolls 12 adults whose lymphoma has returned or who cannot recei…
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New dosing strategy aims to reduce dangerous side effect in blood cancer treatment
Disease control Recruiting nowThis study tests new ways to give the drug sonrotoclax to adults with chronic lymphocytic leukemia or mantle cell lymphoma. The goal is to find a dosing schedule that lowers the risk of tumor lysis syndrome, a serious side effect. About 258 participants will be enrolled to check …
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New skin disease drug enters first human trials
Disease control Recruiting nowThis study tests a new drug called BG-A3004 for the first time in humans. It aims to check the drug's safety and how the body processes it in healthy volunteers and people with immune-related skin diseases. The study is split into two parts: single dose in healthy people and mult…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can targeted drug cocktails erase hidden leukemia cells?
Disease control Recruiting nowThis trial is testing whether combining various chemotherapy and targeted drugs can clear measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who are in remission but still have traces of leukemia cells. The study enrolls patients aged 14 and older with …
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for lymphoma patients: Chemo-Free treatment shows promise
Disease control Recruiting nowThis phase 2 trial tests the drug mosunetuzumab, alone or with zanubrutinib, in 152 adults with newly diagnosed follicular lymphoma who need treatment. The goal is to see how many patients achieve complete remission. Participants receive the drug as injections over several months…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo offers hope for Hard-to-Treat myeloma
Disease control Recruiting nowThis study is for people with multiple myeloma that has come back or stopped responding to other treatments. The trial has two parts: first, finding the best dose of a drug called belumosudil mesylate, and second, testing that dose alone or with dexamethasone to see if it can con…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Promising new treatment for rare Muscle-Weakening disease enters human trials
Disease control Recruiting nowThis study tests a drug called ublituximab for people with a rare autoimmune disease that causes severe muscle weakness. The goal is to see if adding this drug to standard treatment improves muscle strength and function more than standard treatment alone. About 30 adults with ear…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug aims to keep leukemia at bay after first treatment
Disease control Recruiting nowThis Phase 3 trial is testing whether the drug surovatamig can help people with a specific type of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) stay in remission longer after their first round of treatment. About 420 participants will either receive suro…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for Crohn's? large trial tests tulisokibart
Disease control Recruiting nowThis phase 3 trial is testing a drug called tulisokibart in about 1,200 people with moderate-to-severe Crohn's disease who haven't had success with other treatments. The drug is given by IV or injection and aims to reduce symptoms and heal the gut lining. The study compares tulis…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can new drug cocktails beat back Hard-to-Treat leukemia?
Disease control Recruiting nowThis trial is testing several different drug combinations to find the best approach for people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. The study compares the effectiveness and safety of these salvage therapies, aiming to improve rem…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Supercharged immune cells take on Hard-to-Treat myeloma
Disease control Recruiting nowThis trial tests a new approach for people with multiple myeloma that has come back or not responded to treatment. Doctors take immune cells from donated cord blood, genetically engineer them to better recognize and attack myeloma cells, and give them back to the patient along wi…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could a cancer drug fix a bleeding disorder and prevent leukemia?
Disease control Recruiting nowThis early-stage trial tests imatinib, a drug already used for certain cancers, in adults with a harmful RUNX1 gene mutation. The mutation causes easy bleeding and a high risk of blood cancers. The study aims to find the best dose and see if imatinib can improve platelet function…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug candidate SHR-3079 targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis trial tests a new drug called SHR-3079 in adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to at least one prior standard treatment. The main goals are to check the drug's safety, find the best dose, and get an early look at whether it can shrink tumors…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug linvoseltamab aims to stall multiple myeloma in High-Risk patients
Disease control Recruiting nowThis phase 3 trial compares an experimental drug, linvoseltamab, to an existing drug, daratumumab, in 270 people with smoldering multiple myeloma at high risk of developing active multiple myeloma. The goal is to see if linvoseltamab can delay the disease longer. Participants wil…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New scan could spot hidden myeloma earlier
Diagnosis Recruiting nowThis phase 2 trial is testing whether a radioactive tracer called 18F-fluciclovine can detect multiple myeloma better than the standard FDG tracer during PET/CT scans. The study will enroll 60 adults with newly diagnosed or relapsed/refractory multiple myeloma. Each participant w…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
AI eye on the brain: a smarter scan for multiple sclerosis?
Diagnosis Recruiting nowThis trial tests whether an AI tool called icobrain ms can help radiologists detect signs of multiple sclerosis (MS) activity on brain MRI scans. The study involves over 1,300 people with MS or early signs of it, who are already on treatment. The AI analyzes scans and creates str…
Phase: NA • Sponsor: Queen Mary University of London • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Ultrasound and EMG may tell inflammatory from mechanical shoulder issues
Diagnosis Recruiting nowThis study compares muscle thickness around the shoulder blade in people with early ankylosing spondylitis (an inflammatory condition) versus those with mechanical shoulder blade movement problems. Researchers use ultrasound and electromyography (EMG) to see if they can tell the …
Sponsor: Tanta University • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
Blood test could replace needle biopsies for breast cancer staging
Diagnosis Recruiting nowThis study is testing a new blood test called TuFEst that uses DNA fragments and deep learning to stage breast cancer and check if it has spread to lymph nodes. Researchers will enroll 269 breast cancer patients, including those having surgery and those receiving chemotherapy bef…
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Monthly HIV prevention pill could replace daily dose
Prevention Recruiting nowThis phase 3 trial tests MK-8527, a once-monthly oral pill, to prevent HIV-1 infection in women. About 4580 HIV-negative women will take either MK-8527 monthly or a daily PrEP pill (Truvada) to see which works better and is safer. The goal is to offer a more convenient prevention…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Aug 16, 2026 00:00 UTC
-
Monthly HIV prevention pill could replace daily dose
Prevention Recruiting nowThis large phase 3 trial is testing whether a new oral pill called MK-8527, taken just once a month, can prevent HIV infection as well as the standard daily PrEP pill. About 4,390 people at risk of HIV will be randomly assigned to receive either the monthly pill or daily Truvada …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Aug 16, 2026 00:00 UTC
-
Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
Prevention Recruiting nowThis study looks at whether a low dose of the antifungal drug liposomal amphotericin B can prevent serious fungal infections in adults with blood cancers or who have had stem cell transplants and have a prolonged low white blood cell count (neutropenia). The trial enrolls 30 pati…
Sponsor: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine • Aim: Prevention
Last updated Aug 15, 2026 00:00 UTC
-
Dental cleaning may ward off deadly transplant complication
Prevention Recruiting nowThis study tests whether a dental cleaning shortly after a stem cell transplant can prevent chronic graft-versus-host disease (GVHD), a common and serious complication. Researchers will enroll 45 adults receiving a donor stem cell transplant for blood cancer. The goal is to see i…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
New procedure may stop debilitating arm swelling after breast cancer surgery
Prevention Recruiting nowThis study tests a low-risk surgical procedure called LYMPHA, done at the same time as breast cancer lymph node removal, to prevent lymphedema—a chronic, painful arm swelling. About 80 women undergoing breast cancer surgery will be randomly assigned to receive LYMPHA or standard …
Phase: NA • Sponsor: Stanford University • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Can a single shot stop c. diff from returning?
Prevention Recruiting nowThis study tests a new drug called AZD5148 to see if it can prevent repeat C. diff infections in adults. About 230 people will get either the drug or a placebo as a single injection. The goal is to stop the infection from coming back after standard treatment.
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Could a single friendly gut bacterium prevent recurrent c. diff?
Prevention Recruiting nowThis study tests EXL01, a single strain of a beneficial gut bacterium (Faecalibacterium prausnitzii), to see if it can prevent repeat Clostridioides difficile infections in people at high risk. About 56 adults who have had at least two C. diff episodes will take EXL01 or a placeb…
Phase: PHASE1, PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Prevention
Last updated Aug 13, 2026 00:00 UTC
-
New allergy spray trial aims to help teens breathe easier
Symptom relief Recruiting nowThis study tests if Dymista nasal spray safely eases allergy symptoms like sneezing, stuffy nose, and itchy eyes in Chinese teenagers aged 12 to 17. About 100 participants will use the spray twice daily for two weeks. The goal is to see if symptoms improve, not to cure allergies.
Phase: PHASE4 • Sponsor: Viatris Inc. • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
Strumming for the brain: could ukulele lessons sharpen minds in MS?
Symptom relief Recruiting nowThis study tests whether a 12-week online ukulele learning program, called Music-4-MS, can improve cognitive function in people with multiple sclerosis (MS). Half the participants will learn to play the ukulele, while the other half will simply listen to music they enjoy. The goa…
Phase: NA • Sponsor: University of Texas at Austin • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
New eczema drug enters first human tests
Symptom relief Recruiting nowThis early-stage trial is testing a new injectable drug called ARQ-234 in healthy volunteers and people with moderate to severe eczema. The main goals are to check safety and how the body processes the drug, while also looking for early signs that it might improve eczema symptoms…
Phase: PHASE1 • Sponsor: Arcutis Biotherapeutics, Inc. • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
Can tape or a pressure vest ease Post-Radiation breast swelling?
Symptom relief Recruiting nowThis trial tests whether two physical therapies—Kinesio Taping and compression therapy—can relieve breast lymphedema, a common side effect of breast-conserving surgery and radiation that causes swelling, pain, and heaviness. About 99 women who have completed radiation and have ul…
Phase: NA • Sponsor: Tangshan People's Hospital • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
New injection could tame seasonal allergy symptoms for those failed by standard treatments
Symptom relief Recruiting nowThis Phase 3 trial tests an investigational injection called SHR-1819 in adults aged 18 to 75 with seasonal allergic rhinitis (hay fever) who haven't gotten enough relief from standard treatments like nasal sprays or antihistamines. The study compares the drug to a placebo to see…
Phase: PHASE3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
New pill could ease severe eczema itch and rash
Symptom relief Recruiting nowThis study tests an experimental daily tablet (PF-08049820) for adults with moderate to severe eczema (atopic dermatitis). About 165 participants will take either the study drug or a placebo for 12 weeks. Researchers will check skin improvement, itching, and safety through clinic…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
Mind over movement: mental walking practice tested for MS
Symptom relief Recruiting nowThis study tests whether mentally practicing walking while watching videos of people walking can improve gait in people with multiple sclerosis. Twenty participants will either watch walking videos and imagine themselves walking, or watch nature scenes. Researchers will measure m…
Phase: NA • Sponsor: Hacettepe University • Aim: Symptom relief
Last updated Aug 18, 2026 00:00 UTC
-
New CGM training program aims to help seniors with diabetes
Symptom relief Recruiting nowThis study tests a three-session training program to help older adults (65+) who use insulin learn to use a continuous glucose monitor (CGM). Participants will be randomly assigned to the program or standard training. The goal is to see if the program improves how often they wear…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Hypnosis tested as a new tool to sharpen focus in brain injury and MS patients
Symptom relief Recruiting nowThis study explores whether hypnosis can help people with stroke, traumatic brain injury, or multiple sclerosis improve their attention and reduce fatigue. About 48 participants will receive hypnosis sessions alongside standard care, while researchers monitor brain activity with …
Phase: NA • Sponsor: Luzerner Kantonsspital • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Can a gentle electric zap to the brain restore memory in MS?
Symptom relief Recruiting nowThis trial tests whether a mild electric current applied to a brain area linked to memory can improve verbal recall in people with relapsing-remitting multiple sclerosis. Participants will receive either active or sham stimulation during cognitive tasks, and their performance wil…
Phase: NA • Sponsor: The University of Texas at Dallas • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
New study tests online therapy to ease stress for parents of kids with RASopathies
Symptom relief Recruiting nowThis study tests whether Acceptance and Commitment Therapy (ACT), delivered through a smartphone app, can help caregivers of children with RASopathies (like Neurofibromatosis type 1 and Noonan syndrome) cope with parenting stress. The trial is fully remote and involves 70 adult c…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Tailored exercise may ease symptoms of rare blood cancer
Symptom relief Recruiting nowThis study tests whether a 3-month personalized exercise program can improve quality of life, fitness, and symptoms in people with myeloproliferative neoplasms (MPN), a group of rare blood cancers. About 80 participants will be randomly assigned to either start the exercise progr…
Phase: NA • Sponsor: Hannover Medical School • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Can computer games clear the fog? new study tests brain training for ME/CFS
Symptom relief Recruiting nowThis study compares two brain-training programs for adults with ME/CFS who experience brain fog. Both programs include computer games and a mild nerve stimulation device, but one focuses on processing speed and daily tasks while the other emphasizes relaxation and healthy habits.…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
New cream targets itch in eczema patients
Symptom relief Recruiting nowThis study tests a cream called roflumilast 0.15% for itching in people with mild to moderate atopic dermatitis (eczema). About 40 participants aged 12 and older will apply the cream once daily for 4 weeks. Researchers will track how patients describe their itch and other skin se…
Phase: PHASE4 • Sponsor: Integrative Skin Science and Research • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Healing harmonies: music therapy aims to ease stem cell transplant recovery
Symptom relief Recruiting nowThis study tests an online music therapy program that combines mindfulness and music to help people recovering from stem cell transplants for blood cancers. Researchers want to see if it can improve quality of life, reduce pain, fatigue, anxiety, and depression, and possibly spee…
Phase: NA • Sponsor: University of Miami • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Gamified learning boosts diabetes know-how in kids, trial hopes
Symptom relief Recruiting nowThis study tests whether a gamified education program can improve health literacy and quality of life in children aged 8-12 with type 1 diabetes. Half of the 52 participants will receive the gamified program plus standard education, while the other half gets standard education al…
Phase: NA • Sponsor: KTO Karatay University • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
New eczema drug enters first human tests
Symptom relief Recruiting nowThis early-stage study tests a new drug called BBT001 in healthy volunteers and adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. About 198 participants will receive either BBT001 or a placebo, wit…
Phase: PHASE1 • Sponsor: Bambusa Therapeutics • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Could a Cardamom-Bacteria spray soothe your eczema?
Symptom relief Recruiting nowThis study tests if a spray made from ground cardamom seeds and a harmless skin bacteria (Roseomonas mucosa) can improve eczema symptoms in people aged 2 and older. Participants apply the spray 2-3 times a week for 14 weeks and are monitored remotely for about 7 months. Half rece…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Experimental antibodies aim to block cat allergy eye itch
Symptom relief Recruiting nowThis study tests whether two experimental antibodies, given alone or together, can reduce eye allergy symptoms caused by cat dander. About 570 adults and children aged 8 and older with confirmed cat allergy will receive either the antibodies or a placebo. The main goal is to see …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Talking about the end: could guided conversations reduce futile cancer treatments?
Symptom relief Recruiting nowThis trial tests a program called ACT, which trains doctors and nurses to have compassionate, structured conversations with blood cancer patients and their families about end-of-life care. The goal is to help patients understand their prognosis and make informed decisions, potent…
Phase: NA • Sponsor: Christoffer Johansen • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can a magnetic chair ease bowel leakage after J-Pouch surgery?
Symptom relief Recruiting nowThis study tests whether a special chair that delivers high-intensity electromagnetic stimulation can improve bowel leakage (fecal incontinence) and quality of life in people who have a J-pouch after surgery for ulcerative colitis. Participants will sit on the Emsella chair for 2…
Phase: NA • Sponsor: Cedars-Sinai Medical Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can magnetic pulses ease depression and pain together?
Symptom relief Recruiting nowThis study tests whether a non-invasive brain stimulation technique called rTMS can improve symptoms of major depression and chronic pain at the same time. Fifty-four adults with moderate depression and pain will receive 30 sessions of active rTMS over several weeks. Researchers …
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New injection aims to ease arthritis pain in joints
Symptom relief Recruiting nowThis early-stage study tests a new drug called F8IL10, given as an injection directly into the joint, for people with rheumatoid arthritis. The main goal is to find a safe dose and see if it helps reduce joint pain and swelling. About 42 adults with active arthritis in a knee, an…
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Symptom relief Recruiting nowThis study tests a new medicine called ORKA-002 for adults with moderate-to-severe plaque psoriasis. About 160 participants will receive either the drug or a placebo to see if it clears skin and is safe. The goal is to find the best dose and check for side effects over 16 weeks.
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
A guided path back to work after blood cancer: a trial tests the impact
Symptom relief Recruiting nowThis trial tests whether a dedicated 'return-to-work after cancer' consultation can help people who have been treated for blood cancers like leukemia, lymphoma, or multiple myeloma get back to their jobs. The consultation, led by an occupational health specialist with possible su…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Can an online course ease fatigue in autoimmune disease?
Symptom relief Recruiting nowThis study tests an online wellness course that teaches diet, exercise, stress reduction, and self-care to people with rheumatoid arthritis, lupus, Sjogren's syndrome, and similar conditions. Researchers want to see if the program reduces fatigue and improves quality of life. Abo…
Phase: NA • Sponsor: Terry L. Wahls • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Can a daily probiotic soothe colicky babies and calm eczema?
Symptom relief Recruiting nowThis trial tests whether giving formula-fed infants under 5 months a daily probiotic (Bifidobacterium bifidum) can reduce crying time by at least half in babies with colic, and also improve eczema symptoms. Over 8 weeks, half the babies receive the probiotic drops and half receiv…
Phase: NA • Sponsor: University of Roma La Sapienza • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Could a puff of inhaled epinephrine stop severe allergic reactions?
Symptom relief Recruiting nowThis study tests if inhaled epinephrine can quickly ease systemic allergic reactions that happen during allergy testing or treatment. About 100 people aged 12 and older with known allergies will take part. The goal is to see how fast symptoms improve, aiming for a safer and easie…
Phase: PHASE1 • Sponsor: Dr. George Luciuk • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Can a meditation app soothe teen eczema?
Symptom relief Recruiting nowThis trial tests whether regular use of a digital mindfulness meditation app can help adolescents aged 12-17 with moderate to severe atopic dermatitis (eczema) improve disease control and quality of life. Participants will use the app for 10-15 minutes, 3-4 times a week, while a …
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New trial aims to spare breast cancer patients from arm swelling
Symptom relief Recruiting nowThis study compares two ways to treat breast cancer that has spread to nearby lymph nodes: targeted radiotherapy or surgical removal of the nodes. The goal is to see which approach better preserves arm function and reduces the risk of long-term arm swelling. About 1,060 adults wi…
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
HIV study aims to unlock mystery of Post-Treatment immune Flare-Ups
Knowledge-focused Recruiting nowThis study looks at why some people with HIV develop Immune Reconstitution Inflammatory Syndrome (IRIS) after starting HIV medications. Researchers will use PET scans and lymph node biopsies to track inflammation and immune recovery in 300 adults. The goal is to better understand…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists hunt for genetic clues behind rare immune disorder
Knowledge-focused Recruiting nowThis study aims to find the genetic causes of severe combined immunodeficiency (SCID), a rare condition where the immune system doesn't work properly. Researchers will collect blood samples from 100 patients and their relatives to analyze DNA and other factors. The goal is to bet…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Massive study aims to uncover cancer secrets in rare bone marrow diseases
Knowledge-focused Recruiting nowThis natural history study follows up to 4,000 people with inherited bone marrow failure syndromes (IBMFS) and their families to learn why they are prone to certain cancers. Researchers will track health over time, collect genetic samples, and look for clues that separate those w…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists seek genetic clues to mysterious fever diseases
Knowledge-focused Recruiting nowThis study aims to learn more about the genetics and natural history of autoinflammatory diseases, which cause repeated fevers and inflammation. Researchers will study up to 5,000 people, including patients, their relatives, and healthy volunteers. Participants provide blood and …
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
New study aims to crack the code of rare brain disease
Knowledge-focused Recruiting nowThis study is creating the first large database for Niemann-Pick type C (NPC), a rare disease that damages the brain, liver, and spleen. Researchers will collect blood samples and medical records from 100 people with NPC to link their genes with their symptoms. The goal is to und…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists dig into skin bugs to unlock eczema secrets
Knowledge-focused Recruiting nowThis study looks at the tiny organisms living on our skin—like bacteria and fungi—and how they might differ in people with eczema (atopic dermatitis). Researchers will collect skin samples from healthy volunteers and patients aged 2 to 40 with moderate to severe eczema, as well a…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Massive MRI study aims to unlock secrets of MS progression
Knowledge-focused Recruiting nowThis long-term observational study uses MRI scans to track how multiple sclerosis (MS) changes over time in up to 3750 people. Researchers will compare brain images and immune system markers in untreated patients, those on approved therapies, and healthy volunteers. The goal is t…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Can a simple audio diary app transform diabetes Self-Care?
Knowledge-focused Recruiting nowThis study is testing whether a mobile app called Fabla-diabetesMM, which lets people record audio diaries, is easy and helpful for older adults with type 1 or 2 diabetes who also have other health conditions. Thirty participants will use the app and answer questions about their …
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists track rare gene variant to unlock blood disorder mysteries
Knowledge-focused Recruiting nowThis study follows people of all ages who have or may have a RUNX1 gene variant, which can cause bleeding problems and increase the risk of blood cancers. Researchers will collect medical history, blood samples, and bone marrow over many years to understand how the condition deve…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists hunt for genetic clues in Virus-Linked cancers
Knowledge-focused Recruiting nowThis study collects tissue and blood samples from adults with HIV, other immune disorders, or cancers thought to be caused by viruses. Researchers will compare genes in cancer tissue to normal tissue to find genetic changes that drive these cancers. The goal is to better understa…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists seek clues to why some get sick from parasitic worms
Knowledge-focused Recruiting nowThis study looks at how people's immune systems react to infections from parasitic worms, which can cause serious health problems like swelling, blindness, or heart disease. Researchers will evaluate and treat up to 500 participants aged 3 to 100 using standard medical tests and …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists seek clues on white blood cell behavior in allergies and parasites
Knowledge-focused Recruiting nowThis study aims to understand how and why eosinophils (a type of white blood cell) become active in conditions like allergies, asthma, and parasitic infections. Researchers will observe up to 800 people aged 1 to 100 with high eosinophil levels. No experimental treatments are giv…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Can your genes predict eye damage from a common arthritis drug?
Knowledge-focused Recruiting nowThis study looks at whether certain genes make some people more likely to develop eye damage from the drug Plaquenil, which is used for autoimmune diseases like lupus and rheumatoid arthritis. Researchers will compare people who have had eye damage from Plaquenil with those who h…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists launch major study to unravel mysteries of rare immune diseases
Knowledge-focused Recruiting nowThis study aims to understand the causes and progression of Common Variable Immunodeficiency (CVID) and related inborn errors of immunity. Researchers will observe up to 500 patients over time using blood tests, imaging, and other exams. The goal is to find better ways to diagnos…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists seek genetic clues to mysterious immune defects
Knowledge-focused Recruiting nowThis study looks at people with unusual or repeated infections and their family members to find the genetic and biochemical causes of immune system problems. Researchers will collect blood, saliva, urine, and other samples over time to better understand these conditions. The goal…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Cancer tissue bank opens to fuel research
Knowledge-focused Recruiting nowThis study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Can tracking daily life unlock myasthenia gravis mysteries?
Knowledge-focused Recruiting nowThis registry study follows adults with myasthenia gravis (MG) over time to understand how symptoms, daily functioning, and quality of life change. Participants complete surveys about their symptoms, treatments, and challenges, and may share medical records. The goal is to gather…
Sponsor: Autoimmune Neurology Alliance • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
New screening trial aims to speed up matching of cancer patients to the right treatments
Knowledge-focused Recruiting nowThis study tests a new way to screen patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) by analyzing their bone marrow and blood for specific biomarkers. The goal is to quickly match patients with a treatment trial that targets their cancer's unique mark…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists hunt for genetic clues to severe viral infections
Knowledge-focused Recruiting nowThis study looks at people who have had unusually severe or long-lasting viral infections, like serious cases of herpes, HPV, or the flu. Researchers want to find out if these people have hidden immune system or genetic problems that make them more vulnerable. Up to 600 participa…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Can a simple monitor predict type 1 diabetes before symptoms start?
Knowledge-focused Recruiting nowThis study is testing whether a continuous glucose monitor (CGM) can predict blood sugar problems in people who are at risk for type 1 diabetes but have no symptoms. Researchers will follow 75 people aged 5 to 39 who have diabetes-related autoantibodies. They will compare CGM dat…
Phase: NA • Sponsor: Universitair Ziekenhuis Brussel • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Massive study aims to unlock mysteries of rare blood vessel disease
Knowledge-focused Recruiting nowThis study follows up to 4,000 people with vasculitis (a group of diseases that cause blood vessel inflammation) and healthy volunteers over many years. Researchers collect blood, urine, imaging, and genetic samples to learn how the disease develops and changes. The goal is to fi…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
20,000 volunteers needed to decode immune disease genetics
Knowledge-focused Recruiting nowThis study will analyze DNA from up to 20,000 people, including those with immune disorders and their relatives, to find genetic variants linked to conditions like atopy, autoimmunity, and primary immunodeficiency. Researchers will also study how best to return genetic results to…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
New study probes immune system in rare disease patients
Knowledge-focused Recruiting nowThis study looks at how common certain antibodies and inflammatory markers are in people with chronic granulomatous disease (CGD). Researchers will measure levels of adenovirus-fighting antibodies and inflammatory cytokines in blood samples from 60 adults and children with CGD. T…
Sponsor: Ensoma • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists scour lungs for clues to why some get infections
Knowledge-focused Recruiting nowThis study gathers fluid and tissue from the lungs and nose of healthy volunteers and people with a history of lung infections. Researchers will compare samples to find differences in immune function that might explain why some people are more prone to infections. Participants un…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists track rare genetic disorder to unlock its secrets
Knowledge-focused Recruiting nowThis study follows 600 people with GATA2 deficiency, a genetic disorder affecting the immune system and other body systems. Researchers aim to understand the full range of health problems it causes and why it affects people differently. Participants will have yearly check-ups for…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Massive study aims to unlock secrets of Brain's immune attacks
Knowledge-focused Recruiting nowThis observational study is recruiting 2400 people with immune-related central nervous system diseases, such as multiple sclerosis, along with healthy volunteers for comparison. Researchers will use MRI scans, lumbar punctures, blood tests, and neurological exams to track disease…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists seek clues to fungal infections in immune system study
Knowledge-focused Recruiting nowThis study aims to understand why some people are more prone to fungal infections, especially from Candida yeast. Researchers will collect blood, saliva, urine, and tissue samples from people with immune disorders, their family members, and healthy volunteers. No treatment is giv…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Watching and learning: how cancer screenings affect people with fanconi anemia
Knowledge-focused Recruiting nowThis study looks at anxiety related to cancer screenings in adults with Fanconi anemia, a rare condition that raises cancer risk. Researchers will observe 20 participants during their regular screening visits, noting body language, worries, and the clinic environment. No treatmen…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists seek samples to build better Cancer-Killing drugs
Knowledge-focused Recruiting nowThis study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Cancer samples sought to unlock treatment secrets
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Gene hunt in peru: could ancestry hold key to autoimmune diseases?
Knowledge-focused Recruiting nowThis study aims to uncover genetic changes that cause autoimmune diseases in people native to Peru. Researchers will collect blood, urine, and stool samples from 300 participants, including patients with conditions like lupus and rheumatoid arthritis, their family members, and he…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Smart testing after CAR t: could it spare kids from unneeded transplants?
Knowledge-focused Recruiting nowThis study tests whether regular blood and bone marrow tests using advanced DNA sequencing can better monitor children with B-cell acute lymphoblastic leukemia (B-ALL) after they achieve remission with CAR T therapy. The goal is to see if these tests can identify who is truly cur…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Blood cell harvest could fuel future immune disease cures
Knowledge-focused Recruiting nowThis study collects blood stem cells and immune cells from healthy volunteers and patients with primary immune deficiencies or blood disorders. The cells are used in the lab to develop new gene and cell therapies. Up to 850 adults aged 18-70 will participate. The goal is to advan…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists launch Long-Term study to unravel mysterious immune condition
Knowledge-focused Recruiting nowThis study follows 950 people with idiopathic CD4+ lymphocytopenia (ICL), a rare condition where low CD4+ white blood cells raise infection risk. Researchers will track participants for up to 10 years, collecting medical history, blood samples, and infection data. The goal is to …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Scientists launch deep dive into rare liver disease PSC
Knowledge-focused Recruiting nowThis study aims to understand what causes primary sclerosing cholangitis (PSC), a rare chronic liver disease. About 143 adults with PSC will provide blood, saliva, urine, stool, and tissue samples, plus undergo imaging and procedures like colonoscopy and liver biopsy. No treatmen…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
Massive study aims to unlock secrets of immune system diseases
Knowledge-focused Recruiting nowThis study aims to learn more about primary immunodeficiency disorders (PIDs), which weaken the immune system and make people more prone to infections. Researchers will compare genetic and health data from people with PIDs, their healthy relatives, and healthy volunteers to find …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 18, 2026 00:00 UTC
-
New tool aims to ensure blood cancer treatments match patient preferences
Knowledge-focused Recruiting nowThis study tests a decision-support tool called PRIME for adults aged 60 and older with blood cancers like leukemia or lymphoma. The tool helps patients clarify their values and shares that information with their doctors. The goal is to see if using PRIME leads to treatment decis…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can skin biopsies unlock new treatments for scleroderma?
Knowledge-focused Recruiting nowThis study aims to understand the cellular and molecular mechanisms behind systemic sclerosis (SSc), a rare autoimmune disease that causes skin and organ fibrosis. Researchers will collect skin punch biopsies and blood samples from 500 participants, including those with SSc and h…
Sponsor: Relation Therapeutics • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
How does venetoclax work for CLL patients in everyday clinics?
Knowledge-focused Recruiting nowThis study is tracking 500 people with chronic lymphocytic leukemia (CLL) who are taking venetoclax, either alone or with other drugs, as part of their normal care in Austria, Germany, and Switzerland. Researchers want to see how well the treatment works in real-life settings and…
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can discarded bone reveal the secrets to stronger bones?
Knowledge-focused Recruiting nowThis study aims to understand why bones weaken with age, leading to conditions like osteoporosis and osteoarthritis. Researchers will collect bone waste and blood samples from 2,000 people undergoing orthopedic surgery, including those with and without bone disease. By analyzing …
Sponsor: Relation Therapeutics • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Massive study to track what happens when AML comes back
Knowledge-focused Recruiting nowThis observational study will follow 4,000 people whose acute myeloid leukemia has returned or not responded to treatment. Researchers will collect data from routine care to understand survival rates and treatment patterns over up to 4 years. No new drugs are being tested; the go…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Simple blood test may replace colonoscopy for colitis patients
Knowledge-focused Recruiting nowThis study is testing whether a blood test measuring a protein called LRG can tell if the gut lining has healed in people with ulcerative colitis. Researchers will compare blood LRG levels with colonoscopy and tissue samples in 100 patients. If the blood test works, it could offe…
Sponsor: Showa Inan General Hospital • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
MS patients share thoughts on new injection method in major study
Knowledge-focused Recruiting nowThis study follows 842 people with multiple sclerosis who are starting a new under-the-skin injection of ocrelizumab. Researchers will ask participants how satisfied they are with the injection after 1, 6, and 12 months. The goal is to understand patient experience, not to test t…
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Scientists launch major study to track rare immune diseases
Knowledge-focused Recruiting nowThis study is observing up to 3,500 people with immune system problems, including rare genetic conditions like chronic granulomatous disease and severe combined immunodeficiency. Researchers will track how these diseases change over time through blood tests, imaging, and checkups…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Lupus drug anifrolumab under safety microscope: does it raise infection or cancer risk?
Knowledge-focused Recruiting nowThis study watches over 3,000 adults with moderate-to-severe lupus to see if the drug anifrolumab increases the risk of serious infections or cancer compared to standard treatments. No new medicine is given—researchers simply analyze health records from people already prescribed …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Scientists launch major study to unravel rare genetic conditions
Knowledge-focused Recruiting nowThis study aims to learn more about RASopathies, a group of genetic conditions that can cause developmental issues, birth defects, and increased cancer risk. Researchers will follow up to 500 people of any age who have or may have a RASopathy, along with their family members, for…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Scientists hunt for genetic clues to mysterious immune diseases
Knowledge-focused Recruiting nowThis study aims to find the genetic causes of inherited immune problems that affect white blood cells called lymphocytes. Researchers will review medical records and collect blood samples from up to 5,000 people with suspected immune disorders, as well as their relatives. The goa…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
HIV hiding spots revealed in treatment pause study
Knowledge-focused Recruiting nowThis study aims to understand where HIV hides in the body when people stop their daily antiretroviral therapy (ART) for a short time. Fifty adults with HIV will either stay on ART or pause it for up to 90 days. Researchers will use PET/CT scans and take small tissue samples from …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
NIH launches massive study to unlock HIV's secrets through blood
Knowledge-focused Recruiting nowThis study aims to learn more about how HIV infects cells and affects the immune system by collecting blood samples from up to 2,419 adults, both with and without HIV. Researchers will analyze these samples to compare genetic and protein differences. The goal is to better underst…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Simple blood test could predict transplant complications
Knowledge-focused Recruiting nowThis study looks at a new method to measure special immune cells called iNKT cells in the blood of patients who have had a stem cell transplant. These cells may help predict serious complications like graft-versus-host disease (GvHD) and relapse. Researchers will test 75 adults w…
Sponsor: University Hospital Pilsen • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
Knowledge-focused Recruiting nowThis study follows 1,500 people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases — rare conditions where the virus drives abnormal immune cell growth. Researchers will collect medical history, treatment details, and blood samples to see how the diseases beh…
Sponsor: Rong Tao • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Brain chemistry clue may explain why heavy drinkers feel stressed
Knowledge-focused Recruiting nowThis study investigates how acetate, a substance produced when the body breaks down alcohol, is used by the brain in heavy drinkers. Researchers will use a special imaging technique to track acetate metabolism and measure stress hormone levels. The goal is to understand the link …
Phase: NA • Sponsor: Yale University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Why Won't dry eye heal? scientists check nerve damage in GVHD patients
Knowledge-focused Recruiting nowThis study explores whether nerve damage in the cornea causes stubborn dry eye in people with ocular graft-versus-host disease (GVHD), a complication of stem cell transplants. Researchers will measure corneal sensation in 30 GVHD patients and compare it to healthy controls. The g…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Massive lung disease registry aims to unlock secrets of progressive fibrosis
Knowledge-focused Recruiting nowThis registry is following 3,000 adults with idiopathic pulmonary fibrosis (IPF) or other chronic fibrosing interstitial lung diseases (ILDs) to understand how these conditions progress over time. Researchers collect information on symptoms, treatments, quality of life, and store…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New study screens for hidden genetic marker in mysterious mast cell disorders
Knowledge-focused Recruiting nowThis study aims to find how common the KIT D816V mutation is in people with suspected clonal mast cell disease. Researchers will collect blood samples from 450 participants and test them using two sensitive methods. The results may improve understanding and diagnosis of these rar…
Sponsor: Blueprint Medicines Corporation • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can a patient registry unlock the secrets of IBD?
Knowledge-focused Recruiting nowThis study is building a registry of medical information from people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. The goal is to use this data to better understand how IBD develops and progresses, which could help improve future treatme…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
450 russians with rare muscle disease to be tracked in real-world treatment study
Knowledge-focused Recruiting nowThis study watches how doctors in Russia treat adults with a rare muscle-weakening disease called generalized myasthenia gravis (gMG). It does not test any new drug. Instead, it collects information from medical records and routine check-ups for about 450 people over time. The go…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Could a simple blood test flag heart risk in rheumatoid arthritis?
Knowledge-focused Recruiting nowThis study looks at whether certain markers of oxidative stress in the blood are linked to early signs of heart disease in people with rheumatoid arthritis. Researchers will measure these markers and check for thickening or stiffness in the carotid arteries. The goal is to better…
Sponsor: University of La Laguna • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
CLL drug venetoclax under the microscope: genetic clues may improve treatment
Knowledge-focused Recruiting nowThis study tracks genetic changes in chronic lymphocytic leukemia (CLL) cells during treatment with the drug venetoclax. Researchers aim to understand how the cancer evolves as the drug is started. 75 adults with relapsed or refractory CLL will receive venetoclax and undergo regu…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
A simple blood test may reveal hidden infertility risk in young cancer survivors
Knowledge-focused Recruiting nowThis study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …
Sponsor: Erasme University Hospital • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Coin flip chemo: study tests if patients will let a computer choose their treatment strength
Knowledge-focused Recruiting nowThis study looks at whether adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy are willing to let a computer randomly assign them to either lower- or higher-intensity treatment. The goal is to see if this approach is acceptable to patients…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Gene clues may explain lingering blood issues after CAR-T
Knowledge-focused Recruiting nowThis study looks at gene changes that might cause low blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas after CAR-T therapy. About one-third of patients have low blood counts lasting more than 30 days after treatment. Researchers will test blood a…
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can a smarter sleeve beat lymphedema?
Knowledge-focused Recruiting nowThis pilot study tests whether a new compression pattern in a leg sleeve device (Flexitouch Plus) moves lymph fluid better than the current version. Five adults with leg lymphedema will receive both treatments in separate visits, and doctors will measure how far and how often lym…
Phase: EARLY_PHASE1 • Sponsor: Tactile Medical • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can MS drug vumerity be safe during pregnancy? a global registry seeks answers
Knowledge-focused Recruiting nowThis registry study follows women with multiple sclerosis (MS) who become pregnant, comparing those who took the medication Vumerity (diroximel fumarate) with those who took other MS treatments or no treatment at all. The main goal is to estimate the risk of major birth defects i…
Sponsor: Biogen • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can AI learn to grade endoscopy quality from video?
Knowledge-focused Recruiting nowThis study aims to create a large library of recorded endoscopy procedures from adults undergoing upper or lower gastrointestinal exams. The goal is to use these videos to develop and validate artificial intelligence tools that can automatically detect and report quality metrics,…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Wheat sensitivity linked to fatty liver? a new study investigates
Knowledge-focused Recruiting nowThis study looks at whether people with non-celiac wheat sensitivity (NCWS) have a higher chance of having fatty liver or liver scarring. Researchers will compare liver health in people with NCWS to those with irritable bowel syndrome, functional dyspepsia, and celiac disease. Th…
Sponsor: University of Palermo • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can math training rewire Kids' brains? stanford launches new study
Knowledge-focused Recruiting nowThis study from Stanford University is looking at how a 6-week math training program changes brain activity and thinking skills in children with math learning disabilities (dyscalculia). About 180 children aged 6-12 will do math problems on a tablet at home and get weekly one-on-…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Could IBD medications during pregnancy shape a Child's development?
Knowledge-focused Recruiting nowThis study follows pregnant women with inflammatory bowel disease (IBD) and their children for up to four years after birth. Researchers want to see whether the mother's disease activity or use of immunosuppressant or biologic medications affects pregnancy outcomes or the child's…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Rare immune disorder study harvests stem cells to unlock t cell mysteries
Knowledge-focused Recruiting nowThis study aims to collect stem cells from people with a rare condition called idiopathic CD4 lymphocytopenia (ICL) and from healthy volunteers. Participants receive two medications to move stem cells from bone marrow into the blood, where they are collected. The stem cells are t…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Hidden thyroid cancers may be more common in Graves' disease than thought
Knowledge-focused Recruiting nowThis study looks at how often thyroid cancer is found by accident when people with Graves' disease have their thyroid gland removed. Researchers will track 280 adults having this surgery and examine the removed tissue carefully for any cancer, including tiny microcarcinomas. They…
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Family history of blood cancer? new study aims to catch myeloma early
Knowledge-focused Recruiting nowThis study is looking for 2,000 people who have a close family member with a blood cancer like multiple myeloma. The goal is to find early warning signs of the disease by collecting blood samples and health information over time. Participants will not receive any treatment, but t…
Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Gene hunt in newly diagnosed type 1 diabetes adults
Knowledge-focused Recruiting nowThis study is for adults aged 18 to 55 who were diagnosed with type 1 diabetes within the last 6 months. Researchers want to see how many of them carry a specific gene called HLA-DRB1*04:01. Participants will provide a blood sample or cheek swab for genetic testing. The goal is t…
Sponsor: GentiBio, Inc • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can pregnancy and neurological disease coexist safely? a new registry seeks answers
Knowledge-focused Recruiting nowThis study is a pregnancy registry that gathers information from women with chronic neurological conditions like multiple sclerosis, NMOSD, and myasthenia gravis who are planning pregnancy, currently pregnant, or within one year postpartum. Participants can contribute blood, brea…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Blood platelet trends may reveal hidden risk in autoimmune disease
Knowledge-focused Recruiting nowThis study investigates whether changes in platelet counts over time can serve as a dynamic biomarker for disease severity and survival in people with antiphospholipid syndrome (APS), an autoimmune condition that increases blood clot risk. Researchers will track platelet counts f…
Phase: NA • Sponsor: New Valley University • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
New study checks if cancer drug olutasidenib changes how other medicines work
Knowledge-focused Recruiting nowThis study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…
Phase: PHASE4 • Sponsor: Rigel Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Lupus drug anifrolumab under scrutiny for pregnancy risks
Knowledge-focused Recruiting nowThis study tracks 240 pregnant women with lupus who have taken anifrolumab (Saphnelo) to see if the drug affects pregnancy or baby health. Researchers will monitor for birth defects and other complications. The goal is to gather safety information, not to test a new treatment.
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can we predict how kids with IBD will respond to treatment?
Knowledge-focused Recruiting nowThis study follows 1,500 children newly diagnosed with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, to understand why some respond well to treatments while others develop complications. Researchers will collect medical data and biological sa…
Sponsor: Erasmus Medical Center • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Scientists hunt for clues to rare CAR-T side effects in myeloma
Knowledge-focused Recruiting nowThis observational study will follow 30 multiple myeloma patients receiving a standard CAR-T therapy called cilta-cel. Researchers will collect blood, bone marrow, and other samples to find biomarkers linked to rare toxicities like nerve damage, blood issues, and gut problems. Th…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New registry aims to uncover risks of common transplant drug in pregnancy
Knowledge-focused Recruiting nowThis registry follows pregnant women who have taken mycophenolate, a drug used to prevent organ rejection and treat autoimmune diseases. Researchers will collect data on pregnancy complications and birth defects up to one year after birth. The goal is to better understand the dru…
Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New MRI technique could spot lung trouble early in transplant patients
Knowledge-focused Recruiting nowThis study is testing a new type of MRI that uses xenon gas to see how well the lungs are working in people who have had a bone marrow transplant. Researchers will scan 25 transplant patients with or without lung problems, plus 10 healthy volunteers. The goal is to see if this MR…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
AI platform aims to unlock Real-World cancer data on a massive scale
Knowledge-focused Recruiting nowThis study enrolls people diagnosed with cancer to build a large registry using Olivia, an AI-powered health platform. The platform will collect and combine electronic health records and patient-reported outcomes from over 1,000 healthcare systems. The goal is to create a compreh…
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
NIH launches Long-Term study to track stem cell transplant survivors
Knowledge-focused Recruiting nowThis study provides ongoing check-ups for people who received a donor stem cell transplant at the NIH at least three years ago. Researchers will monitor for late side effects, disease return, and overall health. Participants will have yearly visits that may include blood tests, b…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Blood test breakthrough? new study aims to spot rare cancers earlier
Knowledge-focused Recruiting nowThis study looks at a type of immune cell called monocytes in people with certain blood cancers (polycythemia vera, essential thrombocythemia, and myelofibrosis). Researchers will analyze blood samples from 70 newly diagnosed patients to find unique patterns in these cells. The g…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Scientists launch major study to unravel mysterious metabolism disorders
Knowledge-focused Recruiting nowThis study aims to learn more about rare disorders that affect how the body processes chemicals called pyrimidines and purines. These disorders can cause problems in the brain, blood, kidneys, and immune system, ranging from mild to life-threatening. Researchers will compare test…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Could your soap and food be making you sick? new study investigates
Knowledge-focused Recruiting nowThis study looks at how common chemicals in personal care products, processed foods, and synthetic materials affect skin, gut, and airway health. One hundred twenty healthy adults will stay in a controlled hospital room for two 7-day periods—one with filtered air and pure product…
Phase: NA • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Talking gene therapy: new study seeks family insights
Knowledge-focused Recruiting nowThis study interviews patients and families who have experience with gene therapy for rare pediatric diseases, including sickle cell disease. Researchers want to understand their beliefs, attitudes, and what information they need. The goal is to create an online platform with edu…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Could a simple blood test predict clot risk in antiphospholipid syndrome?
Knowledge-focused Recruiting nowThis study asks whether autoimmune hemolytic anemia (AIHA) is linked to a higher risk of blood clots in people with antiphospholipid syndrome (APS). Researchers will compare the number of thrombotic events in APS patients who have AIHA versus those who do not. The study will enro…
Phase: NA • Sponsor: New Valley University • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Scientists watch immune system in action to unlock IBD mysteries
Knowledge-focused Recruiting nowThis study aims to learn how the immune system controls inflammation in the gut for people with Crohn's disease or ulcerative colitis. Up to 1,000 participants aged 0 to 75 will receive standard medical care and may provide blood, tissue, or white blood cell samples. No experimen…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Healthy volunteers key to safer stem cell transplants
Knowledge-focused Recruiting nowThis study collects blood stem cells from healthy volunteers after they receive a growth factor injection. Researchers aim to develop better methods to remove the white blood cells that cause graft-versus-host disease, a serious complication of bone marrow transplants. Up to 500 …
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists seek tissue samples to unlock HIV and cancer mysteries
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Could a lifesaving leukemia drug harm Men's sexual health?
Knowledge-focused Recruiting nowThis study looks at whether tyrosine kinase inhibitors (TKIs), the standard treatment for chronic myeloid leukemia (CML), might be linked to erectile dysfunction (ED) in men. Researchers will track 350 male patients who started TKI therapy, using questionnaires and medical record…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC